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Fungal polyketides are a complex class of natural products with diverse scaffolds.  
The biosynthesis of these molecules involves the iterative condensation of acetate units 
using a minimal set of domains on a single polypeptide. The different levels of reduction 
at each iterative step generates the structural diversity observed via the stuttering action 
of these domains. For some polyketides, further structural complexity is introduced via 
amidation by a nonribosomal peptide synthetase (NRPS) module fused to the polyketide 
synthase (PKS). The NRPS contains a condensation domain (C) that catalyzes the 
coupling of the polyketide to a specific amino acid. Studies by others have suggested that 
PKS function is independent of NRPS activity and thus, this system is amenable to 
combinatorial biosynthesis to generate analogues with different polyketide chains and 
amino acids by performing module swaps. Forging intermodular interactions and 
understanding C domain selectivity for substrates is key to successful engineering of 
these analogues. Herein, I investigate the impact of these factors on the ability to 
synthesize unnatural products by this route. Studying these components required the 
overexpression of chimeric gene constructs, which was anticipated to result in low 
compound yields. Therefore, a novel platform to express fungal genes with yields 
exceeding 1 g per kg media was developed and validated through the characterization of 




to the discovery that C domains are highly selective for closely related substrates in the 
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1.1 Fungal Natural Products 
The contribution of natural products to the survival of the producing organisms is 
not clear in most cases, hence their alternate name of secondary metabolites. In some 
instances, however, they have been found to improve the fitness of the producing 
organisms within their environments by warding off predators and reducing competitors 
for nutrients.1–3 Such biological activities among others have made them invaluable as a 
potential source of medicines. To date, several of these natural products make up a large 
percentage of all drugs in use,4 and fungal natural products have made major contributions 
to this drug compendium over the years. Popular examples of such drugs include 
cyclosporine approved for autoimmune suppression for organ transplant patients in 1983; 
lovastatin for cholesterol management in 1987; and more recently fingolimod, a fungal 
natural product-inspired drug, for the management of multiple sclerosis. Considering that 
the currently identified fungal biodiversity is estimated at a meagre 5% and a biologically 
active molecule is produced by almost every isolated fungal species, fungi remain an 
underexplored resource for drug discovery.5 This reality has been brought into greater 
focus with the advent of the genomics era. Scanning individual fungal genomes for 
biosynthetic genes has revealed that there are more pathways to natural products than the 
number of these molecules isolated from these organisms, suggesting that many of these 
genes have gone silent or are otherwise cryptic under laboratory culture conditions.5–7 
Therefore, vast potential still exists for drug discovery from fungi isolated as far back as 
50 years ago. By characterizing newly discovered fungal species and studying silent 
biosynthetic pathways, it will be possible to tap into the true scientific and medicinal 




 1.2 Cryptic Biosynthetic Pathways 
Current understanding of fungal natural product biosynthesis is that all genes 
involved in the synthesis of a product will be situated at the same locus within the genome, 
a phenomenon otherwise known as clustering.6,8–10 Thus, the presence of more biosynthetic 
gene clusters within a genome than the total number of isolated natural products alludes to 
the presence of cryptic (or silent) biosynthetic pathways.7,11 In order to access molecules 
encoded by these pathways, several strategies have been developed over the years to turn 
on gene expression. One approach has been to change culture conditions.7 By altering the 
nitrogen and carbon sources and mineral composition in growth media, some fungi have 
produced new metabolites. Another strategy relies on recapitulating the interactions that 
go on in the natural environment by coculturing the fungi with various microorganisms.1,12 
With the discovery that gene expression control in fungi is also governed by histone 
methylation and acetylation, epigenetic-modifying small molecules have been added to 
culture media as another strategy to induce expression of cryptic pathways.7 Because the 
aforementioned methods are stochastic processes, they suffer from low success rates and 
have fallen out of favor since the development of fungal genetic techniques. The appeal of 
these genetic methods stems from the fact that they allow direct manipulation of cryptic 
genes. Using common gene cloning techniques, the context of regulation of these genes 
can be altered, which is seen in the controllable overexpression of target genes.13 The most 
common genetic approach is the upregulation of transcription factors found within cryptic 
gene clusters to modulate expression of coclustered genes to produce new secondary 
metabolites.14,15 For instance, aspyridone A from Aspergillus nidulans was discovered by 




of a housekeeping gene promoter.15 Transcription factor overexpression is not a universal 
solution though; there are many examples where it has not resulted in new metabolite 
production, and this approach is also not amenable to fungi for which gene transformation 
methods have not been developed. In addition, general gene transformation techniques for 
fungi do not exist; such a protocol must be developed for each fungus under study.7 These 
shortcomings have led to the development of heterologous expression systems where the 
cryptic genes are transferred from the investigated fungus to a new host.16 Gene expression 
in this host then results in production of the desired metabolite. This approach has the added 
advantage of allowing assignment of roles to individual genes within the cluster towards 
synthesis of the final product. 
  
1.3 Heterologous Gene Expression 
Typically, the gene of interest is cloned into an expression vector and the resulting 
plasmid transformed into the host.16 For expression, the exogenous DNA is either 
maintained as a plasmid or linearized and integrated into the host genome.  Several 
advances in gene cloning technologies such as restriction enzyme ligation and yeast 
recombination have made the construction of such expression plasmids a trivial exercise.17 
Even with these advances, successful expressions depend on the suitability of the host. To 
date, there is a number of heterologous expression hosts that have been developed for 
secondary metabolite expression.18–22 First among them is Escherichia coli, which has been 
used extensively to study polyketide biosynthesis.22–24 While E. coli provides a quick 
expression system because of the short doubling time, it is only suitable for pathways 




cerevisiae has the advantage of dealing well with eukaryotic codon usage,25 but falls short 
by the same measure. Workarounds involve tediously removing the introns by fusion PCR, 
or extracting the coding sequences from prepared cDNA. The latter method has limited 
applicability to cryptic genes and unculturable organisms. To address the intron issue, the 
fungus Aspergillus oryzae has been used with great success to study several fungal natural 
product pathways by direct cloning from genomic DNA.26 However, the reported 
compound yields from the A. oryzae expression system are low. In this dissertation, we 
built a high-yielding expression platform to study recombinant genes from various fungi.  
Unlike previously published systems that use promoters of housekeeping genes, our system 
is based on using regulatory elements of the biosynthetic pathway to equisetin, which is 
produced in large amounts (~2 g L–1) by the filamentous fungus Fusarium heterosporum. 
The identification and characterization of the equisetin biosynthetic pathway is described 
in Chapter 2. How the identified regulatory elements were developed into novel 
heterologous expression tools is detailed in Chapter 3. The application of these tools to 
resurrect an extinct natural product from a cryptic biosynthetic pathway is described in 
Chapters 3 and 4. Furthermore, in Chapter 5, we leveraged this new platform to express 
recombinant gene fusions designed to explore the combinatorial biosynthesis of a class of 
polyketides. A brief introduction to polyketide biosynthesis, relevant to work described in 
this dissertation, is provided below.  
 
1.4 Polyketide Biosynthesis 
The polyketide class of natural products is a structurally diverse group of 




building block, malonyl CoA, they exhibit a large range of structure scaffolds from linear 
aliphatic chains to more decorated quinone-type structures.28 The core domains of 
polyketide synthase enzymes include the acyl transferase domain (AT) involved in 
selecting the extending unit; the ketosynthase domain (KS), which catalyzes the Claisen 
condensation of the malonyl unit with the growing polymer tethered to the acyl carrier 
protein domain (ACP), another core domain. Most fungal polyketides are made by 
synthases that utilize this minimal domain set iteratively to make the backbone polyketide 
chains. In addition to the aforementioned domains, the fungal PKS may have other domains 
that introduce greater complexity such as ?-C-methylations by a methyl transferase 
domain; various levels of reduction through the use of a ketoreductase (KR) domain that 
converts the ?-keto group to an alcohol, a dehydratase domain the reduces the ensuing 
alcohol to an olefin and finally an enoyl reductase (ER) to fully reduce the double bond to 
saturated aliphatic group. The stuttering activity of these modifying domains during the 
iterative chain extension process generates the complexity observed for these fungal 
polyketide scaffolds. In nature, polyketides are often further conjugated with amino acids, 
sometimes forming tetramic acid rings. These molecules have numerous biological 
activities including antibacterial, antiviral, and anticancer properties.29 To date, none of 
these molecules has been further developed into a drug lead largely due to toxicity.   
 
1.5 Polyketide Synthase–Nonribosomal Peptide Synthetase  
(PKS-NRPS) Hybrids  
Tetramic acids are produced biosynthetically by PKS-NRPS hybrid enzymes.27,30,31 




described above, with a nonribosomal peptide synthetase (NRPS) module fused at the C-
terminus (exemplified in Figure 1.1).31 The NRPS module consists of a condensation 
domain (C), an adenylation domain (A), a thiolation (T), and a reductive domain (R). The 
A domain selects a specific amino acid and loads it onto the T domain. The C domain then 
catalyzes the coupling of the polyketide product tethered to the ACP domain of the PKS 
module to the amino acid on the T domain. The final product is then released by a 
Dieckmann cyclization catalyzed by the R domain to form the tetramic acid ring. Within 
this subgroup of fungal polyketides, various amino acid conjugates have been 
characterized.30,32 These have been found to contain homoserine, serine, tryptophan, 
phenylalanine, tyrosine, and alanine, among others (Figure 1.2). This PKS-NRPS hybrid 
system presents a model where combinatorial rearrangements should be possible to yield 
analogues of the natural tetramic acids, containing different polyketide chains and amino 
acid components. However, not much is known about how these modules interact with 
each other. Recently, two such studies reported hybrid products arising from pairing up a 
PKS module with a noncognate NRPS module.33,34 In the first study, the aspyridone 
synthase (ApdA) PKS was expressed alongside the cyclopiazonic synthase (CpaS) 
NRPS.34 Natively, the CpaS NRPS accepts a diketide intermediate; however, the 
interaction with ApdA PKS synthesized a tetrakide-derived tetramic acid. A similar study 
by the Cox group in which the tenellin synthase (TenS) PKS module was swapped with 
DmbS yielded the predicted hexaketide-derived tetramate instead of the pentaketide 
chain.33 These results showed that the PKS could act independent of the NRPS component; 
only after formation of the full-length PKS product did transfer occur. However, work done 
by the Hertweck group in which the PKS module of the lovastatin nonaketide synthase  
 
8Figure 1.1 PKS-NRPS domain order showing the NRPS module (red) fused to the c-
terminus of the PKS module (blue). When the polyketide chain (blue) has been fully 
extended by the PKS, it is transferred by the acyl carrier protein (ACP) to the NRPS by 
coupling to the amino acid (red); this reaction is catalyzed by the condensation (C) domain. 
The intermediate is loaded onto the thiolation (T) domain, and final product release is 












Figure 1.2 Examples of natural products with polyketide scaffolds fused to amino acids 




(LovB) was fused to the chaetoglobosin synthetase (ChaeA) NRPS did not yield the 
expected hybrid product as would be predicted from the earlier studies.32 Through 
relationships inferred from phylogenetic trees, the same study shows that the condensation 
domains of PKS-NRPSs evolved separately from those of LovB-type PKS enzymes and 
thus were not able to accept noncognate intermediates. Central to the modular interactions 
between the PKS and NRPS is the ACP. As mentioned before, the growing polyketide 
chain remains tethered to the ACP until it is fully extended. For PKS-NRPS enzymes, the 
polyketide is offloaded from the ACP by way of coupling to the amino acid; this reaction 
is catalyzed by the C domain. Therefore, productive interaction between the ACP and the 
C domains is required for successful polyketide transfer, in addition to acceptance of the 
polyketide intermediate by the C domain. Understanding the overall interactions of ACPs 
in the context of the PKS-NRPS will allow combinatorial biosynthesis of tetramic acids to 
access new analogues. In Chapter 5, the results of carefully designed studies are reported 
that illuminate C domain selectivity in the context of favorable ACP interactions. Based on 
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ABSTRACT: Equisetin synthetase (EqiS), from the ﬁlamen-
tous fungus Fusarium heterosporum ATCC 74349, was initially
assigned on the basis of genetic knockout and expression
analysis. Increasing inconsistencies in experimental results led
us to question this assignment. Here, we sequenced the F.
heterosporum genome, revealing two hybrid polyketide-peptide
proteins that were candidates for the equisetin synthetase. The
surrounding genes in both clusters had the needed auxiliary
genes that might be responsible for producing equisetin.
Genetic mutation, biochemical analysis, and recombinant
expression in the fungus enabled us to show that the initially
assigned EqiS does not produce equisetin but instead produces
a related 2,4-pyrrolidinedione, fusaridione A, that was previously unknown. Fusaridione A is methylated in the 3-position of the
pyrrolidinedione, which has not otherwise been found in natural products, leading to spontaneous reverse-Dieckmann reactions.
A newly described gene cluster, eqx, is responsible for producing equisetin.
Filamentous fungi are prodigious producers of secondarymetabolites. Within this diverse range of natural products,
polyketides make up a large class, and their biosynthesis has
been the subject of much study over the past decade.1 A
subgroup of polyketides is condensed with amino acids and
cyclized to form 3-acyl pyrrolidinediones, also known as
tetramic acids. These tetramic acids of natural origin are the
product of a polyketide synthase (PKS) fused to a non-
ribosomal peptide synthetase (NRPS) module. In addition to
tetramic acids, fungal PKS-NRPS proteins also lead to the
synthesis of tetramic acid-like compounds, such as pyridinones
and other derivatives that probably result from redox changes
or pericyclic reactions.2,3
In such hybrid proteins, the PKS module belongs to the
family of highly reducing PKSs (HR-PKS), which iteratively
produce complex polyketides through mechanisms that are
incompletely understood.4,5 Typical HR-PKS domains are
universally present in fungal hybrids, including ketosynthase
(KS), acyltransferase (AT), ketoreductase (KR), dehydratase
(DH), C-methyltransferase (MT), and acyl carrier protein
(ACP). Together, these domains are capable of synthesizing
polyketide-derived portions that are α-C-methylated and with
carbons in varying reduction states, including ketone, hydroxyl,
and oleﬁn. In addition, an enoylreductase (ER) domain, which
reduces double bonds, is often present either within the PKS or
as an auxiliary protein.5 In the case of lovastatin biosynthesis,
the ER has been shown to collaborate with the core PKS in the
production of a decalin ring rather than a linear polyketide.6
The NRPS module consists of an adenylation (A) domain
that activates a speciﬁc amino acid, which is loaded onto the
thiolation (T) domain. The covalently loaded amino acid is
then condensed with the fully extended polyketide chain from
the upstream PKS module by the condensation (C) domain. A
Dieckmann cyclization domain (R*) catalyzes the ﬁnal step
that releases the intermediate to form a tetramate, such as
pretenellin A, and prepseurotin A.7−9
Fusarium heterosporum ATCC 74349 produces a large
amount of a tetramate, equisetin 1 (∼2 g L−1 under some
conditions).10 Equisetin is similar to lovastatin 2 in its
polyketide portion, but unlike lovastatin it appends an
additional amino acid, serine (Figure 1). This pattern is very
similar to products synthesized by fungal hybrid PKS-NRPS
enzymes. Because of homology of equisetin to lovastatin, it is
Received: March 5, 2013
Accepted: April 24, 2013
Published: April 24, 2013
Figure 1. Decalin-derived fungal polyketides. The decalin substructure
is similar for equisetin 1 and lovastatin 2. The major diﬀerence
between the biosynthesis of equisetin and lovastatin would be the
formation of the NRPS-derived tetramic acid ring of equisetin, which
is not found in lovastatin.
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expected that, in addition to the core PKS-NRPS protein, an
auxiliary ER would be required.5,6 Equisetin is also amide N-
methylated, which would most likely require an additional,
dedicated MT. Using degenerate PCR and knockout mutation
analysis in F. heterosporum, a previous study identiﬁed three
reducing PKS genes, deg1, deg2, and deg3.10 Through knockout
mutagenesis, deg2 was assigned as being responsible for
equisetin production. This PKS-NRPS hybrid gene was thus
renamed eqiS. The deg2 cluster also contained genes potentially
involved in equisetin biosynthesis, such as additional candidate
ER and MT genes.
A key feature of equisetin biogenesis was that equisetin was
produced at high levels (2 g L−1) only on corn grit agar (CGA),
but no detectable equisetin was produced on many other types
of media.10 In later studies, we sought to exploit this feature for
heterologous expression of fungal genes. Several failed attempts
led us to question whether the equisetin biosynthetic genes had
been correctly identiﬁed. Here, we show through genomic,
biochemical, genetic, and chemical studies that the previously
characterized eqiS is not essential for equisetin production but
instead produces a novel tyrosine-derived 2,4-pyrrolidinedione,
which we named fusaridione A. A second PKS-NRPS gene
found in the genome, deg3, instead produces equisetin. We
renamed the deg2 cluster fsd and the deg3 cluster eqx.
■ RESULTS AND DISCUSSION
fsd Does Not Encode the Equisetin Synthetase. The
deg2/eqiS/fsdS knockout vector, TOPO-deg2KO, contained
elements of the PKS fsdS ﬂanking a phleomycin resistance
marker. Homologous recombination in F. heterosporum
produced a double crossover mutant, FusKO474, as veriﬁed
by PCR. In addition, the previously described eqiS/fsdS
hygroymcin resistance-based knockout, JWS19,10 was resur-
rected from freezer stocks. In previous experiments, JWS19 was
reported to produce no equisetin on CGA after 10 days, while
wild-type F. heterosporum synthesized abundant equisetin.10
However, here we found that both FusKO474 and JWS19
produced abundant equisetin equivalent to that produced by
the wild-type strain on CGA after 21 days of growth
(Supplementary Figure S1). Therefore, fsdS is not involved
directly in equisetin biosynthesis.
Two PKS-NRPS Clusters Identiﬁed in the F. hetero-
sporum Genome. To rapidly identify the correct equisetin
pathway, the whole genome of F. heterosporum ATCC 74349
was sequenced by paired-end Illumina. Automated assembly
availed a genome of 39 Mbp in length with a calculated GC
content of 47.7% on 120 contigs (75% of the genome was on
17 contigs). These genome statistics are very similar to those
for other Fusarium species that have been sequenced, such as F.
graminearum (36 Mbp, 48.3% GC) and F. verticillioides (42
Mbp, 48.7% GC).11 De novo annotation software, Maker2, was
employed to predict a total of 12,448 proteins using the gene
prediction model provided by F. graminearum.12
BLAST analysis of the whole genome (both assembled and
raw reads) identiﬁed only three PKS genes with homology to
the lovastatin nonaketide synthase, which were identical to the
genes previously identiﬁed by PCR.10 In addition, 9 further
PKS genes were present in the genome but lacked any features
consistent with equisetin production (Supplementary Figure
S5). Of these three genes, fsdS and eqxS were PKS-NRPS
genes, whereas deg1 lacked an NRPS portion. fsdS and eqxS
were very similar in domain order and content, although their
protein sequence identity was only 47%. We employed the
SMURF program to analyze fungal secondary metabolite genes
clustered about these PKS-NRPS genes, revealing that both fsd
and eqx clusters encoded at least one regulatory protein, a MT,
a reductase that may function as an ER, and an exporter (Figure
2, Supplementary Tables S5 and S6).13 Therefore, without
functional analysis, these clusters were diﬃcult to diﬀerentiate.
Since fsdS was ruled out as the equisetin synthetase, and since
abundant evidence implicates PKS-NRPS genes in tetramic acid
synthesis, eqxS was a likely candidate.
Pyrophosphate Exchange Assay of FsdS and EqxS.We
reexamined the amino acid substrate speciﬁcity of both the fsdS
and eqxS proteins. A series of His-tagged, adenylation domain-
containing constructs were synthesized to contain varying
combinations of NRPS domains and expressed in E. coli. The
most stable, folded constructs (eqxS A and ATR domains; fsdS
ACP-CATR domains) were puriﬁed and used in the
pyrophosphate exchange assay14 using all 20 proteinogenic
amino acids and N-methyl-L-serine. The major amino acid
activated by fsdS was L-tyrosine, while that activated by eqxS
Figure 2. PKS-NRPS gene clusters found in the F. heterosporum genome. (A) The fsd cluster for fusaridione A (previously known as the eqi cluster).
(B) The eqx cluster for equisetin biosynthesis. Genes including PKS domains are shown in black, including the PKS-NRPS genes fsdS and eqxS and
the trans-ER-like genes fsdC and eqxC. Regulators fsdR, eqxR, and eqxF are shown in white. Other putative enzymes and transporters are shown in
gray, including methyltransferases ( fsdD and eqxD), transporters ( fsdG and eqxG), oxidases ( fsdH and eqxH), and a prenyltransferase ( fsdK). (Note:
overexpression of fsdR did not alter fsd expression, indicating that it may not be part of the pathway; it lies ∼15 kbp from the other pathway genes.).
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was L-serine (Supplementary Figures S3A−D). This implicated
eqx in equisetin synthesis, since equisetin contains Ser, while
fsdS would likely produce a tyrosine-derived molecule.
Mutagenesis of eqx Cluster. Vectors were constructed to
knock out eqxS and clustered genes N-MT eqxD and trans-ER
eqxC. Initially, all vectors were constructed using native
sequences ﬂanking a hygromycin resistance cassette. These
vectors were transformed into F. heterosporum, and trans-
formants were screened for homologous recombination by
PCR (Supplementary Figure S2). While multiple knockout
mutants of eqxC and eqxD were obtained on the ﬁrst attempt,
concomitant knockout of eqxS was unsuccessful. Indeed, over
15 attempts were made to knockout eqxS using three diﬀerent
vectors, using both hygromycin and phleomycin as selection
markers. By comparison, simultaneous attempts to introduce
other genes were successful, usually in the ﬁrst attempt, using
the same materials. Speculatively, this may result from an
untoward phenotype resulting from manipulation of eqxS.
In addition, predicted eqx regulators eqxR and eqxF were
cloned into a phleomycin selection vector so that their
expression could be controlled by the Aspergillus nidulans
alcA inducible promoter and inserted into the genome by
ectopic integration.15−17
N-Methyltransferase eqxD Plays a Role in Equisetin
Biosynthesis. eqxD knockout FusΔeqxD was grown on CGA
for 21 days. Extraction with acetone followed by analytical
HPLC showed that equisetin production was abolished.
Instead, high-level production of an earlier eluting compound
was observed (Figure 3A). By DAD-HPLC, the compound had
the same chromophore as equisetin, and the LC−MS spectrum
showed that the compound was 14 Da lighter than equisetin
(Figure 3B). Puriﬁcation on C18 column with a methanol/water
gradient aﬀorded pure compound 3 (6 mg; isolated yield 240
mg 3 per kg media). The molecular formula of 3 was
determined by FT-ICR ESIMS to be C21H29NO4 (m/z
360.21698 [M + H]+, Δ 0.14 ppm). 1D proton NMR
supported the absence of the N-methyl singlet at δ 3.07
observed for equisetin.18 The 1D and 2D NMR spectra were
essentially identical with those for the previously reported
metabolite trichosetin, a tetramate produced by Trichoderma
harzianum in dual culture with Catharanthus roseus.19 For
example, the 13C spectrum of 3 was essentially identical to that
shown in the previous manuscript. Moreover, all of the
analyzed 2D data were consistent with the proposed structure
for trichosetin.19 Trichosetin is synonymous with N-desmethy-
lequisetin. The chemical speciﬁcity of this result provided
positive evidence associating the eqx cluster with equisetin
production.
Equisetin Biosynthesis Requires trans ER (eqxC)
Activity. The eqxC knockout, FusΔeqxC, was grown on
CGA for 21 days. Extraction followed by analytical HPLC
showed that equisetin was not produced, while the wild-type
strain produced abundant equisetin (Figure 3A). Since a trans-
ER is an integral part of fungal HR-PKS proteins,5 this result
strongly implicated the eqx PKS in equisetin synthesis.
Altered Regulation of eqx Cluster Allows High-Level
Production of Equisetin in Broth Culture. Other than
CGA culture for equisetin production employed by our lab, one
other deﬁned solid-state medium has been reported to induce
F. heterosporum to biosynthesize equisetin.20 Our attempts to
induce the wild-type strain to produce equisetin in liquid
culture by altering both carbon and nitrogen sources were
unsuccessful (unpublished data). To achieve controllable
expression in liquid culture, we cloned the two eqx putative
regulators downstream of the inducible A. nidulans alcA
promoter to make plasmids alcAeqxF and alcAeqxR.
Independent transformation of these plasmids into FusWT
with subsequent selection on phleomycin led to isolation of
transformants Palc:eqxR and Palc:eqxF, which were veriﬁed by
PCR to carry the expression cassette. Spores were prepared
Figure 3. Knockouts and overexpression of eqx pathway genes. (A) Analytical HPLC of crude extracts of eqxC and eqxD knockouts compared to the
wild-type strain (monitored at λ 293 nm). The eqxD knockout mutant does not produce equisetin 1 but instead produces an earlier eluting
compound 3. However, knocking out eqxC abolishes equisetin production, and no new metabolites are observed. (B) LC−MS shows that
compounds 1 and 3 diﬀer by 14 Da. (C) Analytical HPLC-DAD analysis of crude extracts of PDB cultures of F. heterosporum WT and the Palc:eqxR
mutant. Overexpression of eqxR induces equisetin production (top trace shows equisetin standard).
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from each of the mutants and cultured in PDB for 18 h at 30
°C followed by cyclopentanone induction and further
incubation for 4 days. DAD-HPLC analysis of the crude
extracts from mutant cultures compared to the wild-type strain
showed that Palc:eqxR synthesized equisetin at 207 mg L−1
under these conditions. By contrast, neither Palc:eqxF nor
FusWT produced detectable equisetin in liquid broth (Figure
3C). Therefore, eqxR is a positive regulator of the eqx cluster.
Since regulatory elements are often clustered with fungal
biosynthetic pathways, this provided strong positive evidence
for the involvement of eqx in equisetin production.
fsd Pathway Produces a Novel Tyrosine-Derived 2,4-
Pyrrolidinedione. We could not observe any evidence for
production of putative fsd pathway products in a wide variety of
media. In these experiments, we compared the metabolite
expression patterns in the fsdS knockout (FusKO474) with
those of the wild-type strain. This led us to explore another
strategy to determine the secondary metabolite associated with
potential fsdS activity. The promoter of fsdS was swapped for
the A. nidulans alcA promoter to make the fungal expression
plasmid alcAfsdS. Transformation of F. heterosporum with
alcAfsdS led to isolation of a hygromycin-resistant mutant,
Palc:fsdS. A possible trans-ER, fsdC, was also cloned into an
alcA-controlled expression plasmid to generate alcAfsdC, which
was then transformed into Palc:fsdS with phleomycin selection
to generate the cotransformed mutant Palc:fsdSandC. Trans-
formation resulted in colonies that were bright yellow on PDA,
while wild-type F. heterosporum is pink (Supplementary Figure
S4). Both mutants were cultivated in PDB with and without
cyclopentanone induction. The ﬁltered broth was analyzed by
DAD-HPLC. Two new metabolites were produced by both the
Palc:fsdS and Palc:fsdSandC mutants, but the metabolites were
not detected in the FusWT extract (Figure 4A).
The major new metabolite was puriﬁed by C18 chromatog-
raphy to yield a bright yellow compound, fusaridione A (4, 8
mg). The molecular formula was determined by FT-ICR
ESIMS to be C27H31O4N (m/z 434.23267 [M + H]
+, Δ 0.21
ppm). All proton signals except for two exchangeable protons
could be detected in the 1D 1H NMR spectrum. From the
HMQC, HSQC, and HMBC spectra, all 27 carbons were
accounted for: 9 quaternary, 5 methyl, 1 methylene, and 12
methine. Consistent with the pyrophosphate exchange assay
data showing that FsdS activates tyrosine, typical NMR shifts
for tyrosine were identiﬁed, including a p-substituted phenol (δ
7.06 (d) and δ 6.76 (d)) and a benzylic methylene group (δ
3.06(d) and δ 2.84(d)). The α-proton (H-5) of tyrosine was
observed at δ 4.29 and correlated to the phenol ring by TOCSY
via W-coupling. UV maxima were observed at λ 280 nm
(phenol) and at λ 402 nm for an additional conjugated moiety
that was determined to be a pentaene by NMR analysis (Figure
4B). Analysis of the NMR data revealed that the ring is not a
tetramic acid, but instead a pyrrolidine-3-methyl-2,4-dione
(Figure 4C). The structure was further conﬁrmed by observing
3J HMBC correlations from the C-22 methyl protons (H-22, δ
1.46) to the carbonyl carbons, the amide carbonyl (C-2, δ
172.0), and C-4 (δ 207.1) (Figure 5). H-5 and H-6 also showed
HMBC correlations with ring carbonyls.
The pentaene side chain structure was determined by
examination of COSY, TOCSY, and HMBC data, which
unambiguously revealed the positions of vinylic methyl groups.
The attachment of the polyene side chain to the 3-position of
the ring was revealed through an additional 3J HMBC signal
from the C-22 methyl group to the C-7 carbonyl (δ 189.8). The
connectivity shown for the polyene chain was determined from
the HMBC, COSY and TOCSY spectra. From the NOESY
spectra, the trans nature of the double bonds was conﬁrmed.
Figure 4. Overexpression of fsd pathway genes. (A) Analytical RP HPLC of crude mycelial extracts of 7 day PDB cultures of F. heterosporum
transformed with fsdS and fsdC under control of A. nidulans alcA promoter (monitored at λ 380 nm). Two major new metabolites (4 and 5) were
produced by the Palc:fsdS mutant. Introduction of the fsdC gene into Palc:fsdS to make the mutant Palc:fsdSandC did not lead to other products.
(B) UV spectrum of 4 measured by DAD showing maxima at λ 402 nm, λ 280 nm, and λ 224 nm. (C) Structures of 4 and 5 were determined by 1D
and 2D NMR. Metabolite 4 is a novel pyrrolidinedione, and 5 is its ring-opened form.
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The methyl group at the 3-position of the pyrrolidinedione ring
had NOESY correlations with H-5, ﬁxing it anti to C-β of the
tyrosine (Figure 5). The tyrosine S-conﬁguration was
determined by a variation of Marfey’s method.21
A second major compound present in the fsdS expressions
was puriﬁed as a bright yellow compound, 5 (3 mg), which had
a molecular formula of C27H33NO5 (m/z 452.24335 [M + H]
+,
Δ 0.44 ppm), diﬀering from 4 by the addition of H2O. By
DAD-HPLC, the compound had UV maxima at λ 280 nm and
λ 386 nm, diﬀering from 4 by a blue shift for the conjugated
moiety that likely arises from cross-conjugation in comparison
to 4. Indeed, 1D and 2D NMR spectroscopy revealed that 5
was a ring-opened variant of 4 (Figure 4C). For example,
chemical shift data of the tyrosine α-carbon (δ 51.6) was
consistent with a linear, and not cyclic, molecule. A
complicating factor was that the pentaene moiety was present
as a mixture of two tautomers, which could not be resolved by
changing the solvent or changing the temperature from −20 to
+30 °C. HMBC data from both tautomers conﬁrmed the side-
chain structure of the molecule. Puriﬁcation and concentration
of 4 using TFA in the chromatography solvents aﬀorded pure 5,
indicating that 5 is a degradation product of 4 that likely results
from a reverse-Dieckmann reaction. Upon casual observation,
the tautomer problem makes some spectra appear to contain
mixtures, when in fact both 4 and 5 were obtained and analyzed
as pure materials.
Conclusion. Filamentous fungal genomes contain numer-
ous secondary metabolite gene clusters.1,22 In recent years, it
has become clear that most of these clusters are silent.1,2,23,24
To fully exploit fungal pathways, currently the best strategy
employs genome sequencing, followed by any one of several
known methods of eliciting otherwise cryptic pathways.16,17,25
Here, we sequenced the genome of F. heterosporum ATCC
74349 and then used a variety of functional approaches to
elucidate the function of two hybrid PKS-NRPS gene clusters.
We uncovered a novel PKS-NRPS cluster responsible for
equisetin production and reassigned the previously ascribed
equisetin synthetase gene to a novel pyrrolidinedione with
unusual methylation.
Previously, the equisetin synthetase was assigned by
knocking out fsdS, which is synonymous with deg2 and eqiS,
and ﬁnding that equisetin production was abolished in 10-day
fermentations.10 However, the data presented here deﬁnitively
show that this was a misassignment and that the eqx gene
cluster is responsible for equisetin biosynthesis. This previous
study reinforces the well-known danger of relying on primarily
negative data, such as knockout mutagenesis, for functional
assignment of genes. It is remarkable that the fsd and eqx gene
clusters are similar in terms of their biosynthetic content. This
ﬁnding also explains some discrepancies in the literature.
Analysis of fungal PKS-NRPS C domain phylogenies showed
that the previously identiﬁed EqiS fell into a clade that uses
aromatic amino acids, whereas EqiS was reported to use
serine.26 This information was interpreted to indicate polyphyly
in the NRPS modules of fungal PKS-NRPS proteins. Based
upon the evidence here, it is clear that C domain phylogeny is
predictive of amino acid speciﬁcity.
The following lines of evidence support eqx as the equisetin
biosynthetic gene cluster. (1) Only two PKS-NRPS genes ( fsdS
and eqxS) were present in the genome, and other biosynthetic
genes did not have the correct functions for tetramate
biosynthesis. (2) Two diﬀerent fsdS knockouts did not inhibit
equisetin biosynthesis. (3) Knockout of the PKS component
ER eqxC abolished equisetin production. (4) Knockout of the
MT eqxD prevented methylation and led to accumulation of
desmethylequisetin. (5) Overexpression of regulator eqxR led
to eﬃcient synthesis of equisetin in 5 days in liquid culture,
whereas otherwise 3 weeks on solid media is required. While
activation of a regulator can sometimes activate a remote
biosynthetic gene cluster as well as the adjacent cluster,27 in this
case strong induction led to a single product that was attributed
to the adjacent cluster. Taken together, this provides both gain-
and loss-of-function experiments demonstrating that eqx is
crucial for equisetin production. Because eqx contains broadly
similar genes to those found in fsd, the biosynthetic scheme is
likely identical to that previously proposed (Figure 6).10
fsdS was apparently silent since no metabolites could be
attributed to this pathway, despite controlled experiments in
which wild-type was compared to fsdS knockouts in multiple
conditions. Alternatively, it is possible that the ﬁnal products of
the pathway are unstable or otherwise diﬃcult to isolate. Upon
induction under artiﬁcial conditions, fsdS led to production of
the highly unstable product fusaridione A 4. This product is
likely not the natural product, as the other genes in the cluster
were not coexpressed, except for the putative ER-like gene,
fsdC. Other genes located in chromosomal proximity to fsdS
encode proteins such as a potential prenyltransferase (FsdK)
Figure 5. Key NMR data for 4 and 5.
Figure 6. Proposed biogenesis of equisetin. The PKS module of EqxS
together with the enoylreductase (EqxC) catalyze the formation of the
polyketide unit (blue) which is then conjugated to L-serine (red) by
the condensation domain of the NRPS module. Activity of the
Dieckmann cyclase domain (R*) results in release of the intermediate
as the tetramate, trichosetin. Subsequent N-methylation is carried out
by EqxD to give equisetin.
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and a cytochrome p450 oxidase (FsdH). It is possible that the
putative ER does not function as an enzyme in the fsd pathway.
Alternatively, the products of some of the other proteins (such
as FsdK or FsdH) may be the substrates of FsdC. It should be
emphasized that FsdC is likely not an ER, as its sequence is
only distantly related to other characterized trans-ER
sequences.
Compound 4 bears structural similarity to products of other
fungal PKS-NRPS proteins, such as the proposed prepseurotin
A9 and the known pretenellin A28 metabolites. In addition, it is
similar to the known fungal products, militarinones, for which
the biosynthetic genes have not been characterized.29 There-
fore, the proposed biosynthesis of 4 is consistent with what is
known about fungal PKS-NRPS metabolism (Figure 7). The
polyketide is synthesized by incorporation of the equivalent of
seven acetate units. Every extension requires participation of
the KS, AT, and ACP domains. KR and DH domains produce
double bonds at every possible position except for C-7, which
remains in the ketone oxidation state. As with other fungal
polyketides, methyl groups would be introduced by a dedicated
C-methyltransferase domain within the PKS, which acts at C-3,
-10, -14, and -16. Subsequently, through the action of C, A, and
T domains, tyrosine is activated and appended to the
polyketide chain.
The major substantive diﬀerence between 4 and previously
known compounds is the methyl group at C-3. Because of this
methyl group, the product of the Dieckmann condensation 4 is
readily degraded via the reverse-Dieckmann reaction in the
course of fermentation or when treated with acid. Previously, it
was shown that the R* domain in tetramic acid synthetases
releases the Dieckmann product.7,8 In the synthetic literature, it
is reported that α-substituted, β-diketones readily undergo the
reverse-Dieckmann reaction due to the lack of possible
resonance stabilization.30 Therefore, these results, in tandem
with the known activity of R* domains, are consistent with an
enzymatic release of 4, followed by a nonenzymatic hydrolysis
to yield the linear product 5.
In conclusion, we have identiﬁed and assigned equisetin
production by F. heterosporum to a new PKS-NRPS gene
cluster, eqx. In addition, the product of the PKS-NRPS (FsdS)
of the previously reported cluster has been characterized to be a
novel compound, (3R,5S)-5-(4-hydroxybenzyl)-3-methyl-3-
((2E ,4E ,6E ,8E ,10E)-4,8,10-trimethyldodeca-2,4,6,8,10-
pentaenoyl)pyrrolidine-2,4-dione.
■ METHODS
Gene Cloning and Analysis Methods. DNA was obtained from
Escherichia coli and yeast using the QIAprep Spin Miniprep Kit
(Qiagen) and from F. heterosporum using the DNeasy Plant Mini Kit
(Qiagen). DNA was ampliﬁed by PCR using high-ﬁdelity enzymes
Platinum HiFi Taq (Invitrogen) or Phusion Hot Start II HiFi
(Finnzymes). Clones were analyzed using Platinum Taq (Invitrogen).
Ampliﬁed fragments were cloned into destination vectors using yeast
recombination in Saccharomyces cerevisiae BY4741, using a previously
described lithium acetate method,31 or by TOPO TA cloning
(Invitrogen). The yeast-derived plasmids universally contained an E.
coli replicon and resistance marker as well as the described32 yeast
plasmid elements. Plasmid rescue from yeast was performed using E.
coli TOP10 (Invitrogen). Vectors used in this study, their construction
methods, and primer sequences are provided in Supporting
Information.
Fungal Mutagenesis. Vectors were cloned using hygromycin33 or
phleomycin34 resistance markers. Gene knockout vectors were
obtained by ﬂanking resistance markers with ∼2 kbp of F. heterosporum
target DNA on each side. Overexpression vectors were obtained by
fusing genes in frame with the cyclopentanone-responsive promoter
alcA.15,17 Linearized plasmids (10 μg) were transformed into F.
heterosporum following a previously reported method,10 except that the
protoplasting buﬀer was modiﬁed to contain the following (in 20 mL):
Trichoderma lysing enzyme (1 g), yatalase (100 mg), hemicellulase (30
mg), and β-glucuronidase (5 mg). Transformants were regenerated for
17 h at 30 °C on regeneration broth (1 M sucrose, 0.02% Difco yeast
extract) and then plated on regeneration broth/1% agar with the
appropriate selection agent (hygromycin 150 μg mL−1 or phleomycin
150 μg mL−1). Colonies were screened by PCR to determine whether
DNA was inserted via homologous recombination or ectopically. All
screens for homologous recombination employed primer sets where
the PCR product is ∼8-fold larger if homologous recombination has
occurred. Screens were employed both on colonies and on mature
mycelia after weeks of growth to ensure integrity and purity of
recombinant clones.
To knockout fsdS, phleomycin-resistance knockout vector TOPO-
deg2KO was transformed into F. heterosporum by the protoplast
method to yield FusKO474. eqxC and eqxD knockout vectors TOPO-
OxoKO and TOPO-MTKO were synthesized similarly, except using
the hygromycin resistance marker. Several eqxS knockout vectors were
synthesized using both the hygromycin and phleomycin markers.
To overexpress proteins in F. heterosporum using alcA, transcription
factors eqxF (alcAeqxF) and eqxR (alcAeqxR) were transformed into
F. heterosporum using phleomycin selection, while fsdS (alcAfsdS) and
fsdC (alcAfsdC) were transformed under hygromycin and phleomycin
selection, respectively. A double mutant was constructed containing
both alcAfsdS and alcAfsdC.
Genome Sequencing and Analysis. F. heterosporum DNA was
sequenced at the University of Utah Huntsman Cancer Institute
sequencing facility on an Illumina HiSeq 2000. A single lane was
sequenced in a 100 bp paired-end sequencing run. The resulting raw
reads were trimmed to provide reads >40 bp in length and with a
PHRED quality score >30. The highest quality assembly was obtained
using VELVET with the k-mer value of 61 and 235 x coverage.35 The
sequence was autoannotated with Maker2 using Augustus de novo gene
prediction parameters, with Fusarium graminearum as the model
organism.12,36 BLASTx analysis was performed using a variety of
polyketide genes as queries; to detect the closest relatives to lovastatin,
residues 9−445 of the lovastatin nonaketide synthase (AAD39830.1)
Figure 7. Proposed biogenesis of fusaridione A. The PKS module of
FsdS catalyzes the formation of the polyketide unit (blue) which is
then conjugated to L-tyrosine (red) by the condensation domain of the
NRPS module. Activity of the Dieckmann cyclase domain (R*) results
in release of the intermediate as fusaridione A. The unstable
pyrrolidinedione ring of fusaridione A is opened through a reverse-
Dieckmann reaction to aﬀord 5.
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were used in the search. Supplementary Tables S3 and S4 provide
genome statistics and e-values for BLAST results.
Pyrophosphate Exchange Assay. The eqxS A and ATR
domains, as well as the fsdS ACP-CATR, were constructed as N-
terminal His-tagged sequences, as described in Supporting Informa-
tion. The eqxS constructs were expressed in E. coli Rosetta 2DE3
(Novagen). The cultures were grown in 2XYT broth supplemented
with ampicillin and chloramphenicol at 225 rpm and 30 °C until an
OD600 of 0.4 was attained. The temperature was then reduced to 18
°C, IPTG (100 μM) was added, and the cultures were incubated for
18 h. fsdS ACP-CATR was expressed in E. coli BL21(DE3), to which
the chaperone plasmid pG-KJE8 (Takara Bio Inc.) had been added.
Protein expression was performed as above, except that the medium
was Luria−Bertani (LB) broth, and the inducers were L-arabinose (2
mg mL−1) and tetracycline (2 ng mL−1) in addition to IPTG (100
μM).
Cells were harvested, ﬂash frozen, and stored at −80 °C. Thawed
cell pellets were resuspended in lysis buﬀer (5 mL g−1 cell pellet; 50
mM Tris, 200 mM NaCl, 10 mM imidazole, 5% glycerol, pH 7.5) and
stirred on ice for 1 h with lysozyme (600 μg mL−1). Cells were
sonicated at 30% amplitude for 3 min with 30 s on/oﬀ cycles on the
VibraCell 750 instrument and then incubated on ice for 30 min with
DNase (20 μg mL−1) and 10 mM MgCl2. Following centrifugation at
20,000g for 45 min, the supernatant was ﬁltered and loaded onto Ni-
NTA resin. The resin was washed twice (1 M NaCl, 30 mM imidazole,
pH 8.0), and proteins were eluted (1 M NaCl, 200 mM imidazole, pH
8.0) and dialyzed (25 mM HEPES, 500 mM NaCl, pH 8.0). fsdS ACP-
CATR was further puriﬁed by FPLC on an SD300 column attached to
an AKTA puriﬁer, using the dialysis buﬀer. Puriﬁed proteins were
analyzed by SDS-PAGE and ﬂash frozen at −80 °C for storage.
The enzymes were used in the pyrophosphate exchange assay
following a previously published protocol.14 Enzymes were used at 1
μM, and all 20 proteinogenic amino acids and N-methyl-L-serine were
used at 2 mM. A control reaction was performed with no amino acid
added. Experiments were carried out in duplicate, and background was
subtracted using the no amino acid control.
Chemical Analysis of Fungal Transformants. HPLC was
performed using a Hitachi LaChrom Elite System with diode array
detection using the Agilent Eclipse XDB C18 column (4.6 mm × 150
mm, 5 μm) for analytical purposes and the Discovery HS C18 column
(25 cm × 10 mm, 5 μm) for preparative puriﬁcation. Analytical mass
spectrometry was performed using the Agilent ZQ, while high-
resolution FT-ICR experiments were performed at the University of
Utah Mass Spectrometry Core Facility using the LTQ-FT (Thermo-
Electron) instrument. NMR data was acquired on a Varian INOVA
500, except for an HMBC spectrum of 4 acquired on a Varian INOVA
600 equipped with a cryoprobe.
Veriﬁed transformants were grown on PDA (Difco) for 4 days to
generate spores, which were harvested by suspending the spores in
sterile water with an inoculating loop followed by ﬁltration through a
cotton plug.10 Fresh spores were used to inoculate media for all fungal
expression experiments. In all analytical experiments, wild-type strains
were used as simultaneous controls.
Spores from knockout mutants were transferred to CGA10 and
incubated at RT for 21 days prior to harvesting. Cultures were
harvested by extracting three times with acetone (200 mL per 100 g
media). The acetone was dried by rotary evaporation, leaving an
aqueous residual. For analytical HPLC and LC−MS, this residual was
desalted over a plug of end-capped C18 resin and analyzed directly. To
purify compound 3, a 100 g CGA culture was used, and the residual
water was acidiﬁed to pH 2.0 with H2SO4 (conc) and extracted four
times with hexanes (100 mL).37 The extract was dried by rotary
evaporation, resuspended in boiling hexanes (100 mL), and ﬁltered.
The hexanes fraction was washed six times with ethanol (2 mL) and
dried by rotary evaporation; 25% of the residue was further puriﬁed by
ﬂash chromatography on end-capped C18 using a methanol/H2O
gradient, with TLC analysis employing a ferric chloride stain. Fractions
containing 3 (90% methanol elution) were dried by rotary evaporation
to give known compound trichosetin 3 (6 mg):19 1H and 13C NMR,
see Supplementary Table S7; HRMS, see Supplementary Figure S22.
Spores from overexpression mutants were transferred to PDB
(Difco) and incubated for 18 h with shaking at 200 rpm at 30 °C. To
induce alcA, cyclopentanone (30 mM ﬁnal concentration) was added,
and the cultures were incubated for 6 d. Cultures were ﬁltered through
MiraCloth and subsequently extracted. For eqxF and eqxR over-
expression, the ﬁltered broth (250 mL) was extracted with ethyl
acetate (2 × 250 mL) containing 1% acetic acid. The solvent was
removed by vacuum, and the dried residue was subjected to analytical
HPLC. The amount of equisetin 1 in the crude extract of the
Palc:eqxR culture was quantiﬁed by HPLC using a standard curve
generated with pure equisetin. For fsdS and fsdS-fsdC overexpression
experiments, mycelia were extracted with acetone (200 mL), and the
dried residue after solvent removal was puriﬁed by ﬂash chromatog-
raphy on end-capped C18 using an acetonitrile/water gradient, with
TLC analysis employing iodine on silica as a stain. One fraction
containing 4 was dried by vacuum to give pure compound fusaridione
A 4 (8 mg). The ﬁltered broth (4 L) was extracted with ethyl acetate
(2 × 2 L) acidiﬁed with 1% acetic acid. The separated organic layer
was dried under vacuum, and a portion of the residue was subjected to
analytical HPLC. Flash chromatography on end-capped C18 using a
methanol/H2O (0.1% TFA) gradient was employed to isolate 5.
Fractions containing 5 were pooled, and solvent was removed under
vacuum. Final puriﬁcation was done with several rounds of preparative
HPLC to aﬀord pure compound 5 (3 mg). For 1H and 13C NMR data
of 4 and 5, see Supplementary Table S8; for HRMS, see
Supplementary Figures S23 and S24.
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ABSTRACT: Strategies are needed for the robust production of
cryptic, silenced, or engineered secondary metabolites in fungi.
The ﬁlamentous fungus Fusarium heterosporum natively
synthesizes the polyketide equisetin at >2 g L−1 in a controllable
manner. We hypothesized that this production level was
achieved by regulatory elements in the equisetin pathway,
leading to the prediction that the same regulatory elements
would be useful in producing other secondary metabolites. This
was tested by using the native eqxS promoter and eqxR regulator
in F. heterosporum, synthesizing heterologous natural products in
yields of ∼1 g L−1. As proof of concept for the practical
application, we resurrected an extinct pathway from an
endophytic fungus with an initial yield of >800 mg L−1, leading
to the practical synthesis of a selective antituberculosis agent. Finally, the method enabled new insights into the function of
polyketide synthases in ﬁlamentous fungi. These results demonstrate a strategy for optimally employing native regulators for the
robust synthesis of secondary metabolites.
Because of new technologies in sequencing and bioinformatics,
it is now relatively trivial to identify novel biosynthetic
pathways to secondary metabolites in cultivated organisms
and in the environment.1 Research in this area has led to a
renewed appreciation that many secondary metabolites have yet
to be described and that a vast resource awaits discovery.2,3
Although pathway identiﬁcation is simple, discovering the
compounds produced by these pathways remains much more
challenging, especially when the pathways are silent or encoded
in the genomes of uncultivated organisms. To obtain the new
compound, in many cases, the identiﬁed genes must be
transferred to a new host and successfully expressed.4 Despite
many advances in technology, this is still nontrivial.
To date, many heterologous expression hosts have been
developed for secondary metabolite production.4−8 Most of
these focus on expression of bacterial biosynthetic pathways, for
which numerous hosts exist. For eukaryotic pathways, such as
those from ﬁlamentous fungi, genes have been heterologously
expressed in Escherichia coli, Saccharomyces cerevisae, Aspergillus
oryzae, and several other yeasts and ﬁlamentous fungi.5−7,9,10
Practical scale production of fungal compounds in bacteria has
proven to be challenging.4 S. cerevisae provides a robust
platform but with relatively modest puriﬁed yields. Additionally,
it does not handle introns well, requiring that introns be
removed prior to expression. Similarly, heterologous expression
platforms in various ﬁlamentous fungi have led to relatively
modest yields, although in many cases fungal introns are
tolerated, allowing genomic DNA to be employed directly.5,9
These expression systems generally use housekeeping or related
primary metabolic promoters that induce robust transcription
of the desired genes, indicating that perhaps seeking improve-
ments in level of transcription alone is insuﬃcient to provide
high levels of secondary metabolites, and suggesting room for
the development of other strategies.
Here, we sought to take advantage of high-titer production of
equisetin in the ﬁlamentous fungus Fusarium heterosporum
ATCC 74349.11,12 F. heterosporum produces equisetin at ∼2 g
L−1 on corn grit agar (CGA), yet production is undetectable
(10 ng L−1 detection limit) in many other types of media. We
thus hypothesized that if an exogenous biosynthetic gene was
placed under the control of the equisetin biosynthetic regulon,
the heterologous compound would be synthesized in a yield
similar to that observed for equisetin in the wild-type strain.
Moreover, the highly controlled regulation of the equisetin
locus might enable the production of compounds that are
natively toxic to F. heterosporum. This strategy bears similarity
to that previously used in actinomycetes to synthesize
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polyketides13 but stands in contrast to a commonly used
strategy in ﬁlamentous fungi, wherein promoters or regulators
from primary metabolism are used to produce recombinant
polyketides.
Using the model described below, we produced several
heterologous fungal polyketides in F. heterosporum. In fungi,
polyketides are biosynthesized by iterative decarboxylative
condensation of malonyl units.14,15 The minimal domains
that make up the polyketide synthase (PKS) include
acyltransferase (AT) domain, which selects the substrate; acyl
carrier protein (ACP), which tethers the growing chain during
extension; and the ketosynthase (KS) domain, which catalyzes
the condensation reaction.14−16 In addition, PKS enzymes may
contain other modifying domains such as the methyltransferase
(MT) domain, which introduces varying patterns of C-
methylations along the polyketide backbone. For the
reducing-type PKS, varying levels of reduction are achieved
by ketoreductase (KR), dehydratase (DH), and enoyl reductase
(ER) domains.14 In general, all domains required to produce a
fungal polyketide are contained on a single polypeptide, but for
several PKSs, the ER is trans-acting and is translated as a
separate polypeptide from the other PKS domains.17−20 In the
latter case, the trans-ER protein is required to produce the
natural product. In many fungi, PKS modules exist as hybrids
with nonribosomal peptide synthetases (NRPS), resulting in
formation of polyketides fused to amino acids.10,15,21,22 Unlike
standalone PKSs that rely on hydrolysis via a thioesterase
domain (TE) for product release, several PKS-NRPSs use a
terminal reductase (R) domain, which catalyzes a Dieckmann
reaction in tandem with product release to form a tetramic acid
ring.23,24
Here, we describe a platform that enables production of
heterologous fungal secondary metabolites in high titers (∼1 g
L−1 unoptimized yield). The platform was applied to several
problems in biosynthesis and drug discovery, including
resurrection of a silenced pathway of potential use in
tuberculosis.
■ RESULTS AND DISCUSSION
Design of Expression Strategy. The strategy was based
upon prior knowledge of the regulation of equisetin
production. Equisetin biosynthesis requires the coordinated
action of the PKS EqxS, the auxiliary ER EqxC, and the N-MT
EqxD (Figure 1).11 The ﬁrst two of these are synthesized from
genes that are divergently transcribed from a promoter region,
peqxS. A regulatory transcription factor, EqxR, drives
production of equisetin.11 On CGA media, a large amount of
equisetin is produced, while on other media such as potato
dextrose agar (PDA; Difco) or potato dextrose broth (PDB;
Difco), equisetin is not produced.11 Equisetin is constitutively
produced on CGA and slowly accumulates over a 21-day
period. We thus selected peqxS as a platform for producing
metabolites, under control of EqxR. In this conception, the
peqxS region also contains a hypothetical gene, eqx3, which is
commonly found in equisetin-like pathways. For simplicity, this
region was left in place in the current study. In some vectors,
we used only one-half of peqxS to express genes in one
direction; in this series, eqx3 is disrupted, and the promoter
region is referred to as peqxS′. In others, the bidirectional
promoter region peqxS was used; in these cases eqx3 is not
disrupted.
While the wild-type regulator eqxR was well controlled to
produce equisetin solely on CGA, we envisioned applications in
which we might desire more rapid production in liquid media.
In previous work, we fused the alcA promoter (palcA) with
eqxR (Figure 1C).11 While palcA is inducible, it exhibits
signiﬁcant basal expression. Indeed, palcA-eqxR led to
constitutive production of equisetin even in broth.11 However,
production yields were lower in broth, and there was a concern
that toxic metabolites may delay or halt fungal growth under
control of palcA-eqxR. By contrast, an advantage of the PDB
method was that production could be achieved in 5−7 days,
rather than the 21+ days used with CGA. The strategy thus
took advantage of this strong control of equisetin production. If
toxicity was a concern or if high yields were required, the wild-
type eqxR construct was used. For a faster assessment of
whether a recombinant metabolite could be produced, the
palcA-eqxR construct could be employed. In this study, we
employed two strategies to introduce palcA-eqxR: (1) we
recently reported a modiﬁed F. heterosporum strain, Palc:eqxR,
which overexpresses the equisetin positive regulator eqxR under
control of the alcA promoter to allow equisetin production in
broth culture after 5 days, whereas normally no equisetin is
produced in liquid broth;11 (2) we included the palcA-eqxR
Figure 1. Model of the regulation of equisetin production. (A) The wild-type equisetin biosynthetic gene cluster, eqx, contains genes encoding
biosynthetic proteins (green), a transcription factor (blue), and a promoter region used in this study (peqxS, red). (B) In the wild-type F.
heterosporum, equisetin is produced when the fungus is grown on corn-derived media. A model is that the transcription factor gene eqxR is
transcribed, leading to transcription of the pathway via peqxS. Shown is transcription of eqxS and eqxC, which together produce the desmethyl-
equisetin analog, trichosetin, which is shown at left. (C) In support of this transcriptional model, when the heterologous promoter palcA is placed in
front of eqxR, production of equisetin becomes constitutive and no longer depends upon growth on corn.
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gene in an expression vector that could be transferred to F.
heterosporum, along with desired secondary metabolic genes.
We had two major concerns in terms of practical genetics:
could we repetitively use a single promoter element, and could
we process diﬀerent classes of introns? F. heterosporum largely
undergoes ectopic recombination in our hands, and it is quite
diﬃcult to obtain homologous recombinants. For this reason,
we believed that repetitive use of peqxS would be tolerated by
the strain, enabling production of more than two gene products
without recombination. Indeed, in this study, we show that
multiple copies of this element are stable in recombination,
meaning that the strategy is scalable to recapitulate multigene
biosynthetic pathways. We were also concerned about the
ability to splice diﬀerent types of introns. While this will
presumably always be a problem in some cases, here, we show
that a quite divergent set of introns can be processed. However,
our overall strategy mainly uses artiﬁcially spliced, intron-free
DNA.
Our construction strategy involved using shuttle vectors, in
which we could employ yeast recombination in S. cerevisiae25 to
build the desired vectors, E. coli to amplify those vectors, and F.
heterosporum for production of compounds. Each vector thus
required selection and replication elements for each strain (see
Methods). We constructed and tested multiple types of
selection markers so that multiple diﬀerent vectors could be
inserted into F. heterosporum. Previously, we used hygromycin
(hph) and phleomycin (ble) resistance eﬀectively.11 Here, we
also employed uracil auxotrophy as an additional selection
marker.26 By combining these elements, it becomes possible to
use stepwise engineering to insert multiple copies of genes
under control of peqxS. In addition, it is always possible to
insert multiple copies of the promoter into a single vector prior
to transformation into F. heterosporum, making the strategy
highly scalable.
Finally, we used an 8-cutter restriction endonuclease site,
either AscI or PacI, to linearize the vectors before fungal
transformation. These sites were selected so that the linearized
vectors would contain the complete promoter-heterologous
gene construct in the correct order. Otherwise, there was a
danger of integration with a disrupted reading frame. In
addition, we put these sites in some cases between selectable
markers and synthetic green ﬂuorescent protein (sGFP) to
ensure that the vector was inserted in the correct manner.
However, in the event, we never found a rearrangement that
necessitated using sGFP. In F. heterosporum, linearized vectors
integrated ectopically and intact.
Below, we describe a stepwise application of these principles
to construct a heterologous expression platform. (1) The basics
of transcription using both wild-type eqxR and palcA-eqxR were
examined using sGFP. Although simple chemical analysis of
equisetin production previously revealed fundamental aspects
of pathway regulation, employing sGFP enabled a direct
translational readout that would complement our under-
standing of eqxR and peqxS. (2) We desired to test this
strategy by adding a single, discrete, heterologous PKS that
leads to a known and well characterized product. We selected
the cpaS gene from the Aspergillus f lavus cyclopiazonic acid
pathway for this purpose. Not only is cpaS exceptionally well
characterized,9,27 but A. f lavus is in a diﬀerent class (Euro-
tiomycetes) from Fusarium (Sordariomycetes). (3) We next
tested the applicability to systems requiring two genes for
production of compounds. In the event, we used both the
homologous equisetin pathway11 and the heterologous
lovastatin pathway, again from an Aspergillus.19 By examining
equisetin production, we hoped to determine whether
chromosomal location impacted production; in the event, it
did not. The lovastatin PKS genes are well characterized17,19,28
and biomedically of great importance, making this an
interesting target for production. Moreover, only two proteins
are required to synthesize the complex core of the molecule.
(4) We aimed to produce more than two genes and to test the
practical application of the platform to a real-world problem.
This involved production of the “extinct” metabolite,
pyrrolocin. Taken together, these approaches fully deﬁne the
application of equisetin regulatory elements to produce diverse
secondary metabolites in high yield.
Knockout of the eqx Locus. We desired to compare
expression in the wild-type F. heterosporum with expression in
an eqx knockout strain. Although eqxC has been previously
deleted, eqxS was diﬃcult to delete. Here, we created a
knockout vector in which eqxS, eqxC, eqxD, and the promoter
region peqxS were deleted (Figure 2). The resulting strain,
FusΔeqx5 was conﬁrmed to be an eqx cluster knockout by PCR
(Supporting Information Figure S4). Subsequent genome
sequencing of FusΔeqx5 revealed that the eqxS gene was
knocked out in the 5′ end and that the deletion vector was
inserted into a total of 3 locations in the genome (Supporting
Information Figure S5).
eqxS Promoter Drives Expression of sGFP in
Recombinant Strain. To test whether the peqxS promoter
sequence could be used to express exogenous genes, and to
determine timing and control of heterologous expression, the
peqxS′ was fused to sGFP and transferred to wild-type F.
heterosporum in vector FH-1 (Figure 3A; Supporting
Information Figure S1). After 21 days on CGA, sGFP was
observed in fungal ﬁlaments when examined by confocal
ﬂuorescence microscopy. Moreover, the fungus was ﬂuorescent
over the full expression period on CGA, but it lacked any
observable ﬂuorescence on PDA. This was a clear indication
that peqxS′ was suﬃcient for heterologous expression. It also
further supported previous observations that production was
constitutive on CGA but completely shut oﬀ on PDA and other
media. By contrast, when sGFP was added to strains containing
the leaky palcA-eqxR gene (Figure 3B), the resulting F.
heterosporum strain was constitutively ﬂuorescent on all media.
Expression of the cpaS Gene from Aspergillus f lavus
Produces Expected Metabolite. To determine whether the
peqxS′ could lead to biosynthesis of new compounds, the well-
characterized cpaS gene from Aspergillus f lavus was cloned into
FH-1 to make pHygB-Cpas. The resulting F. heterosporum
Figure 2. Knockout of eqx genes. (A) The wild-type gene cluster. (B)
Previously, eqxC was deleted with hph. (C) Here, this eqxC knockout
was extended to delete peqxS and eqxC and to disrupt the 5′-regions of
eqxS and eqxD, using the ble marker. This knockout required the prior
deletion of eqxC and did not work in the wild-type strain.
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mutant, Peqx:Cpas, was then cultured in potato dextrose broth
(PDB) for 7 days. The predicted product, cAATrp 1 was
identiﬁed by high pressure liquid chromatography (HPLC)
(Figure 4A) and isolated. Comparison of the 1H NMR
spectrum and the molecular formula of 1 with those of the
previously reported cAATrp showed that they were identical
(Supporting Information Figure S13).23,27 This conﬁrmed the
value of peqxS′ in producing heterologous compounds.
However, high levels of equisetin 2 were coproduced (Figure
4A).
In other systems, it has been shown that eliminating the
production of undesired metabolites increases substrate ﬂux to
the target pathway resulting in higher yields of the desired
compounds.5 In our case, we reasoned that deleting the
equisetin biosynthetic genes would not only increase ﬂux of the
building block, malonyl CoA, to polyketide-type heterologous
pathways, but also ease downstream target compound
puriﬁcation and analysis. The A. f lavus cpaS gene was cloned
into vector FH-2 (Supporting Information Figure S2), which
contained a copy of palcA-eqxR for constitutive expression in
broth. An sGFP tag was fused to the C-terminus of cpaS. After
transformation of this construct into the eqx knockout strain
FusΔeqx5, we isolated a mutant Δeqx5:Peqx:CpaSgfp that
glowed bright yellow on a dark reader (Figure 3B). This strain
was cultured in 100 mL PDB for 7 days, extracted, and the
extract analyzed by HPLC-DAD to show that 1 was robustly
produced, while equisetin was absent (Figure 4B). Production
of 1 was measured to be 100 mg L−1 by HPLC-DAD in
comparison with a standard curve. This is an order of
magnitude greater than the previously reported production of
the same compound when the cpaS was expressed in A. oryzae
under control of a housekeeping promoter.27 In addition, this
experiment provided some support for our hypothesis, since
the yield in the deletion mutant was increased by approximately
4-fold in comparison to production in the wild-type equisetin
producer.
When the Δeqx5:Peqx:CpaSgfp mutant was cultured for 21
days on CGA, production of 1 rose to over 1 g kg−1 without
any optimization of production conditions. A. f lavus is quite
phylogenetically distant to F. heterosporum, with the former in
Class Eurotiomycetes and the latter in Class Sordariomycetes,
indicating that the strategy may be widely applicable to fungal
metabolites from diﬀerent groups.
Use of the Divergent Promoter for Simultaneous Dual
Gene Introduction. In initial experiments, only one side of
peqxS was used, comprising 1.5 kbp of gene sequence. To
express two genes, peqxS was synthesized, containing the entire
∼2.5 kbp of the divergent promoter, to generate vector FH-3
(Figure 5A). Previously, we showed by knockout mutagenesis
that eqxC was critical for the production of equisetin 2 and
trichosetin 3, and we proposed that it was the trans-acting ER
for the equisetin pathway.11 Here, we showed the direct
involvement of eqxS in the biosynthesis of trichosetin 3. Both
eqxS and eqxC were cloned into vector FH-3 under control of
the divergent eqx promoter. In initial experiments, eqxS was
fused with a C-terminal sGFP tag so that we could readily
conﬁrm protein expression. The resulting vector, hpheqxC
+eqxSgfp, was transformed into FusΔeqx5. The isolated
transformants were brightly ﬂuorescent, demonstrating appro-
priate gene expression under control of the divergent promoter.
In addition, the ﬂuorescence was constitutively obtained on
PDA, further demonstrating the constitutive regulation of the
pathway under control of leaky palcA.
Dieckmann Cyclase Depends upon Unmodiﬁed C-
Terminal R Domain. To our surprise, trichosetin was not
detected by HPLC-DAD in the crude extracts of the isolated
mutants (Figure 5B). Instead, close inspection of the LC/MS
trace showed a new product 4 heavier than trichosetin by 18
Da, but with a similar fragmentation pattern (Figure 5C;
Supporting Information Figure S11). Compound 4 was
characterized by NMR experiments, including 1H, 13C,
Figure 3. Monitoring peqxS′-driven transcription with sGFP. (A)
sGFP was placed immediately downstream of peqxS′ and cloned into
the wild-type fungus. The wild-type control (left) was compared with
the transformed fungus (right) on CGA. Shown is a single corn grit
from a 21-day CGA culture, by confocal microscopy. Fluorescence was
constitutive on CGA, but not visible on other media. Fungal ﬁlaments
can be seen glowing green, over the red autoﬂuorescent background.
(B) sGFP was tethered to the gene, cpaS, downstream of the peqxS′
promoter. The resulting vector also contained the constitutive palcA-
exqR regulator. Shown here is a photograph of constitutively
ﬂuorescent fungal colonies grown on PDA, visualized on a Dark
Reader.
Figure 4. Expression of CpaS and production of cAATrp (1). (A)
Expression in the wild-type F. heterosporum strain. HPLC-diode array
detection (DAD) analysis of crude extracts of PDB cultures of
Peqx:Cpas mutant and the Palc:eqxR control. The eqxS promoter
drives expression to avail expected product 1. Coproduction of
equisetin 2 is observed. (B) Expression in eqx knockout strain.
Production of 1 is improved, and equisetin 2 is no longer observed.
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gCOSY, gHSQC, and gHMBC, to be the ring-opened
derivative of trichosetin that had not undergone the terminal
Dieckmann reaction.23,24 This result implied that eqxS is indeed
the equisetin synthetase, but the gfp tag interferes with the
proper functioning of the reductase domain, preventing
Dieckmann cyclization and instead promoting water-mediated
hydrolysis of the intermediate. This was, in fact, found to be the
case because, when eqxS was cloned without a C-terminal tag,
trichosetin was robustly synthesized at wild-type levels (Figure
5B).
Production of Multiple Gene Products Leads to
Synthesis of Lovastatin Precursors in F. heterosporum.
To establish the utility of this new expression strategy for
coexpression of heterologous genes, we cloned the well-studied
lovastatin nonaketide synthase (lovB) from Aspergillus terreus
together with its cognate trans-ER (lovC)19 to make the
hphlovC+lovBgfp plasmid. We also cloned only lovB into FH-3
to make the plasmid hpheqxC+lovBgfp. Transformation of
these constructs independently into FusΔeqx5 resulted in
production of the expected products. Without its cognate trans-
ER, the expressed LovB synthesized the previously reported
truncated intermediates, 5 and 6 (Figure 6A).19 Coexpression
of lovB with lovC produced the expected reduced metabolites 7
(Figure 6A), the dihydromonacolin L acid 8, and the lovastatin
precursor lactone 9 (Figure 6B).19,29 These metabolites were
characterized by comparing their liquid chromatography/mass
spectroscopy (LC/MS), ultraviolet (UV), and 1H NMR data to
previous reports (Supporting Information Figures S8−S10,
S12−S14). This conﬁrmed that, indeed, the intergenic
sequence between eqxS and eqxC could guide transcription
divergently to heterologously coexpress two genes. The puriﬁed
yield of 9 was 130 mg kg−1, and 8 was produced in about equal
Figure 5. Trichosetin synthesis requires EqxC and unmodiﬁed EqxS.
(A) Expression vector FH-3 designed with complete intergenic
sequence peqxS, for dual expression of genes. Also shown are elements
that permit cloning by recombination in S. cerevisiae and selection in E.
coli. (B) Analytical HPLC of crude extracts of PDB cultures of
FusΔeqx5 transformed with eqxSgfp together with either eqxC or
noncognate trans-ER lovC. Also shown is nontagged eqxS coexpressed
with eqxC and the trichosetin standard. Trichosetin is only produced
in the presence of eqxC and unmodiﬁed eqxS. (C) LC/MS analysis of
crude extracts shows that a gfp tag on the C-terminus of EqxS
interferes with formation of trichosetin and instead results in
production of only the ring-open form 4.
Figure 6. Dual expression with peqxS promoter reconstitutes pathway
to lovastatin precursor. (A) Analytical HPLC of crude extracts of PDB
cultures of FusΔeqx5 transformed with lovBgfp together with lovC or a
noncognate trans-ER eqxC. In the presence of eqxC, lovB produces the
polyene pyrone 5 and ketone 6; and more reduced pyrone 7 with lovC
coexpression. (B) LC/MS analysis of crude extracts shows formation
of the lovastatin precursor, dihydromonacolin L acid 8 and the lactone
9 when lovBgfp is coexpressed with lovC. EqxC is not able to
complement LovB to form 8 or 9.
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amounts, indicating that the initial unoptimized yield should
exceed ∼300 mg kg−1.
EqxS Requires Cognate trans-ER. In the course of
cloning and analyzing lovC, we coexpressed lovC and eqxS
under control of the divergent promoter. No trichosetin was
produced under these conditions (Figure 5B). LovC could not
complement EqxC, indicating that EqxS could not interact with
the noncognate ER. Further, the complementary experiment in
which EqxC was coexpressed with LovB failed to yield reduced
intermediates (Figure 6A). By contrast, the ERs were fully
functional when coexpressed with their cognate PKS proteins.
Resurrection of Antituberculosis Agent from a
Silenced Biosynthetic Pathway. In collaboration with
scientists at Wyeth (now Pﬁzer), researchers in the Barrows
lab cultivated an endophytic fungus, designated strain NRRL
50135, obtained in Papua New Guinea as part of their
International Cooperative Drug Discovery Group (ICBG)
project. The crude extract was potently active against
Mycobacterium tuberculosis, and assay-guided puriﬁcation led
to the identiﬁcation of a novel compound, pyrrolocin A (10), as
the active principle. In 2007, a tentative structure 10 was
assigned based upon HRESIMS and NMR (Figure 7A), but the
amount of compound was not suﬃcient to assign the
stereochemistry or to perform further activity tests. Unfortu-
nately, the fungus ceased producing the compound after the
initial isolation experiments, which is an extremely common
phenomenon in natural products research, so that the project
could not be further pursued or published. Numerous attempts
at modifying production conditions, using many diﬀerent
published methods, failed to resurrect the synthesis of this
potentially important compound. This presented the perfect
challenge to test the application of our new production
platform. The goal was to resurrect production in F.
heterosporum, in tandem with greatly increasing the production
level so that the compound could be further developed.
We sequenced the NRRL 50135 genome, which after
assembly was found to be 54.1 Mbp on 5809 contigs
(calculated GC content is 47.5%). Autoannotation software
predicted 17722 proteins. From the preliminary structure of 10,
we predicted its biosynthesis would be similar to that of
equisetin,11 requiring a PKS-NRPS, trans-ER, and MT. BLAST
analysis of the predicted proteins using EqxS as a query
produced only 2 PKS-NRPS genes in the entire genome. When
the database was queried with EqxC, the top hit was on the
same 50.7 kbp contig as the identiﬁed top hit obtained with the
EqxS query (Figure 7B). These genes were subsequently
designated prlS and prlC, in analogy with the equisetin
nomenclature. However, we could not ﬁnd an MT that
coclustered with either of the PKS-NRPS genes. Instead,
distantly similar genes (37% identity to the equisetin N-
methyltransferase, EqxD) were found unclustered with any
PKS.
Since production of 10 was predicted to require coexpression
of more than two genes, we created a derivative strain of
FusΔeqx5, in which the strain was transformed into the uracil
auxotroph, FusΔeqx5ΔpyrG10, by directed knockout of the
orotidine 5′-phosphate decarboxylase gene (pyrG). A comple-
ment vector for this auxotroph was constructed using the native
F. heterosporum pyrG, to create expression vector FH-4
(Supporting Information Figure S3). The prlS and prlC
sequences were then cloned into FH-4 and used to transform
strain Δeqx5ΔpyrG10 to prototrophy. An isolated mutant
ΔpyrG:Peqx:prlS+prlC was cultured in 250 mL PDB for 5
days. The crude extract contained pyrrolocins B (11) and C
(12), the desmethyl derivatives of 10 (444 Da [M + H]+).33
Compounds 11 and 12 (Figure 7C) were produced in a 2:1
ratio, totaling >800 mg kg−1 on CGA, which is greatly in excess
of what was initially found for 10 in the native producer before
production was lost (∼50 mg L−1).
Two MTs were cloned in attempts to methylate the
tetramate ring. The ﬁrst, PrlD, was the top hit resulting from
BLAST analysis of NRRL 50135 when EqxD was used as the
query (36% identity). prlD was from a contig that was not
linked with prl, meaning that it might result from a separate
biosynthetic pathway. EqxD itself was also coexpressed with
PrlS and PrlC. Each MT was cloned into complementary vector
FH-1 and separately transformed into F. heterosporum
ΔpyrG:Peqx:prlS+prlC. The mutants were cultivated for 7
days. Analysis of the crude extracts by HPLC-DAD and LC/MS
showed that both PrlD and EqxD led to synthesis of
methylated products. Interestingly, the EqxD-expressing strain
Figure 7. (A) Preliminary structure of antituberculosis agent 10 with
mass 458 Da (M+H)+ initially isolated from endophytic fungus NRRL
50135. (B) The identiﬁed candidate gene cluster for the biosynthesis
of 10 after genome sequencing contains a PKS-NRPS hybrid gene
prlS, an enoyl reductase prlC, two transcription factors prlF and prlR,
and two exporter genes prlG and prL. (C) Analytical HPLC of crude
extract of FusΔeqx5ΔpyrG10 transformed with both prlS and prlC
driven by the eqxS promoter shows synthesis of two new products 11
and 12 with corresponding mass of 444 Da (M+H)+. Further
introduction of methyltransferases prlD and eqxD led to synthesis of
new minor products 13 and 10, respectively. (D) Compounds 11 and
12 were found to have antituberculosis activity and to have the core
structure of 10.33
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produced a minor amount of authentic pyrrolocin A 10 (<10
mg kg−1) in a background of ∼800 mg kg−1 of nonmethylated
11 and 12. The methylated derivative 13 produced by the PrlD-
expressing strain did not match the NMR data for 10 and is
therefore not the correct MT. No obvious MT exists in the
sequenced genome that would be predicted to perform that
transformation.
Conclusion. Heterologous expression is potentially the
most universal solution to produce natural products from
cryptic pathways and unculturable organisms.4,5 We set out to
develop such a production platform based on the equisetin
biosynthetic regulon, which would enable production of
important metabolites with suﬃcient yield to ease puriﬁcation
and downstream assays. This platform was designed based
upon the hypothesis that high-level transcription alone was
insuﬃcient to produce high levels of secondary metabolites.
Instead, exploitation of a natively high-producing biosynthetic
pathway would provide the ideal environment for secondary
metabolite biosynthesis. In developing and testing this
platform, we designed derivative strains of F. heterosporum
and a suite of expression vectors into which various
heterologous genes could be cloned. These new tools were
validated by producing a range of fungal polyketides from
widely diﬀerent fungi, in unoptimized yields ranging from
several hundred mg to >1 g per liter. In fact, we found that
cultures on just 50 g of CGA provided enough material for
complete characterization of novel compounds. We provided
proof of concept by resurrecting an important silenced
pathway.
Another advantage of this platform is that it seems to process
introns from a broad phylogenetic diversity of fungi. prlS and
prlC contained introns that were properly processed (otherwise
interrupting the reading frame of the proteins), demonstrating
the breadth of the platform in handling introns from diverse
strains. As has been found in other heterologous expression
strategies, a disadvantage is that pathway shunt products are
often produced along with the major natural product. However,
in this case, the abundant amount of desired products
compensated for this problem.
We have demonstrated practical application of this platform
in reviving antituberculosis activity previously observed from
pyrrolocin A, a product of the NRRL 50135 strain. Direct
cloning of prlS and prlC from genomic DNA of strain NRRL
50135 into our expression vectors and subsequent high-level
production of related active compounds 11 and 12
demonstrated the ease with which such eukaryotic genes
ridden with introns could be characterized. This work enabled
the structures of the pyrrolocins to be fully elucidated and the
biological activity to be characterized.33
This strategy is widely applicable to many types of natural
product synthesis in diﬀerent organisms. The key factors that
led us to select F. heterosporum as the production host were as
follows: (1) the robust synthesis of the native compound,
which meant that even if the recombinant yield were greatly
reduced it should still be suﬃcient for chemical analysis; (2) the
strict controllability of compound production, where essentially
no natural product is produced on most media types, leading to
a reduction in problems related to toxicity; (3) the apparent
constitutive expression of the natural pathway, where
compounds are slowly produced, exported, and accumulated
in the medium over the course of weeks on CGA. It is likely
that other systems with similar features would be amenable to
the same approach.
A few biochemical observations were also enabled by these
studies. During the complementation of the eqx knockout strain
with eqxC and eqxS, we directly show that both these genes are
required for equisetin production. However, we found that R
domain function is altered when fused to an sGFP tag. Instead
of the expected tetramic acid 3, we obtained the ring-open 4.
We speculate that sGFP alters the structure of the R domain to
prevent either transfer from the T domain or to allow water to
enter the R domain active site. The tetramic acid derivative is
nearly instantaneously formed from thioesters under neutral
buﬀer conditions in water,24 making it especially remarkable
that the linear form can be obtained from thiotemplated
synthesis. Potentially, if desired, this problem might be
circumvented by experimenting with diﬀerent types of linkers
that do not disrupt the R domain. A cleavable linker strategy
may also be feasible. However, in our hands, we found that
sGFP is optional; for example, the complete vector is usually
integrated intact in F. heterosporum. We also found that the ER
proteins cannot be crossed between these pathways but that the
wild-type ERs are required at least in these cases. The
interaction of these ER proteins is also of interest, since having
the correct set of protein partners is essential in the synthesis of
the desired natural products.
In the wild-type fungus NRRL 50135, 10 was the major
compound produced, with a small amount (<1% estimated
from HPLC-MS) of 12 as a side-product.33 Based upon the
sequenced gene cluster and the recombinant expression
performed here, it is clear that the combination of PKS-
NRPS and auxiliary ER lead to the formation of 12. Unlike our
ﬁndings here, the wild-type fungus did not produce any cis-
decalin product, such as 11. It is possible that one of the other
hypothetical genes in the gene cluster could be responsible for
this discrepancy and may act as the pyrrolocin Diels−Alderase,
but there are also other interesting possibilities. Of note, no
obvious MT was present in the prl cluster that might produce
10. The closest homologue of EqxD from the genome did not
produce 10. By contrast, EqxD itself produced ∼10 mg kg−1 of
10. This minor production, using a combination of
heterologous and homologous proteins, would likely not have
been observable if starting with a less eﬃcient expression
system. This emphasizes the value of starting with a high-
yielding platform. The yield was still suﬃcient for biological and
chemical characterization from a single 1 kg scale experiment.
The reaction with EqxD is also remarkable in that 12 contains
D-Ser, while 3 contains L-Ser, and the decalin ring is also
enantiomeric between 3 and 12. This indicates that, perhaps,
EqxD has fairly relaxed substrate selectivity.
■ METHODS
Cloning of Vectors and Expression Plasmids. Standard
PCR techniques were employed and plasmid construction
carried out as previously described.11 Details of vector
construction can be found in the Supporting Information.
Vector images were generated with Vector NTI software
(Invitrogen).
Transformation of Fusarium heterosporum was done as
previously described except that protoplasts were prepared
from 8 to 10-h germinating spores.11 When antibiotic selection
was required, hygromycin or phleomycin was added to media at
150 μg mL−1. For uracil auxotroph selection, protoplast
regeneration agar lacking uracil was prepared containing 1 M
sucrose, 0.02% yeast extract without amino acids, 0.02% BSM
supplement, and 1% agar.
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Fungal Mutagenesis. Knockout of eqxS FusΔeqx5 was
constructed by transforming FusΔeqxC with knockout vector
ClusterPhleoKO (Supporting Information) and transformants
selected on phleomycin. The knockout cassette was made of
the phleomycin resistance marker ﬂanked by sequences
homologous to regions within eqxS and eqxD (Figure 2).
Isolated transformants were counter-screened for hygromycin
sensitivity and veriﬁed by colony PCR. The genome of the
identiﬁed knockout FusΔeqx5 was extracted and sequenced.
The reads were aligned to the FusWT reference genome11 with
Novoalign and output visualized with the integrative genomics
viewer30 (Supporting Information Figure S5).
Generating the Uracil Auxotroph. The pyrG knockout
cassette in the TOPO-pyrGKO plasmid was made by cloning a
randomly selected sequence (ﬁrst exon of lovC) into the F.
heterosporum pyrG sequence. Translation of this sequence
results in a truncated, nonfunctional PyrG. FusΔeqx5 was
transformed with TOPO-pyrGKO, and the protoplasts were
regenerated for 72 h at 30 °C before plating on selection
medium made of Czapek Dox Broth, 5-FOA (4 g L−1), uracil
(1.12 g L−1), uridine (140 mg L−1), and 1.5% agar.
Transformants were cross-streaked on Czapek−Dox agar with
and without uracil to identify auxotrophs. Diagnostic PCR for
homologous integration was done to conﬁrm FusΔeqx5Δ-
pyrG10 as a true knockout (Supporting Information Figure
S6).
Fluorescence Microscopy. Visualization of gfp expressing
mutants on CGA was done on an Olympus FV1000 spectral
confocal microscope. Visualization of gfp expressing mutants on
PDA was done on a Dark Reader (Clare Chemical).
Genome Sequencing and Analysis. All fungal genomes
were extracted with the DNeasy Plant Minikit (Qiagen) and
sequenced at the University of Utah Huntsman Cancer
Institute sequencing facility on an Illumina HiSeq 2000.
The raw reads from NRRL 50135 genome sequencing were
assembled using the SPAdes de novo genome assembler31 with
a kmer range from 31 to 85. Autoannotation of the genome was
done using Augustus.32 To locate the pyrrolocin biosynthetic
cluster, BLAST analysis was done using EqxS, EqxC, and EqxD
sequences as queries.
Chemical Analysis. Selected transformants were screened
for compound production by culture in potato dextrose broth
(PDB) for 7 d at 30 °C with shaking at 180 rpm. Spores of
compound expressing mutants were then inoculated on to corn
grit agar and incubated at room temperature for 21 d.
Extraction of ﬁltered PDB broth was done with ethyl acetate
containing 1% acetic acid, and CGA was wholly extracted with
acetone. Solvents were removed under vacuum, and the crude
extracts analyzed by HPLC-DAD and LC/MS using C18
chromatography.
Puriﬁcation of cAATrp 1. The crude extract from a PDB
culture (250 mL) of Δeqx5:Peqx:CpaSgfp was puriﬁed by
preparative HPLC (4 mL min−1; 5−70% acetonitrile/water-
0.05% TFA in 35 min). The pooled fractions were dried under
vacuum to aﬀord pure 1 (9 mg), which was then analyzed by
1H NMR and LC/MS (Supporting Information Figures S7 and
S13), in comparison to previously published reference data.23,27
A standard curve was generated using pure 1 by HPLC-DAD
and production was quantiﬁed from crude extracts of 100 mL
PDB cultures and 50 g CGA cultures of Δeqx5:Peqx:Cpasgfp
to average 100 mg L−1 and 1.25 g/kg (±0.24 g kg−1, n = 3),
respectively.
Puriﬁcation of 4. CGA culture of Δeqx5:Peqx:eqxC
+eqxSgfp (50 g) was extracted with acetone. The crude residue
was then fractionated by ﬂash chromatography on end-capped
C18 with a methanol/water gradient and fractions screened by
LC/MS. The fraction containing 4 was further puriﬁed by
preparative HPLC to aﬀord previously undescribed compound
4 (4.7 mg), which was characterized spectroscopically (see
Supporting Information).
Puriﬁcation of Dihydromonacolin L 9. The crude extract
from 50 g CGA culture of Δeqx5:Peqx:lovC+lovBgfp was
fractionated by ﬂash chromatography on end-capped C18 with
a methanol/water gradient. Fractions were screened by LC/MS
and 9 was found to be contained in one fraction. This fraction
was dried, and the residue was separated on silica column with
2:1 ethyl acetate/hexanes mobile phase. Further preparative
HPLC puriﬁcation aﬀorded 9 as a white solid (6.6 mg). MS and
1H NMR data were compared with those for the previously
reported material.19
Puriﬁcation of 10−13. To purify 11, the crude extract
from 200 g CGA culture was fractionated by ﬂash
chromatography on end-capped C18 using a methanol/water
gradient. The fractions were analyzed by HPLC-DAD, and a
portion (12.5%) of the fraction containing 11 was puriﬁed by
several rounds of preparative HPLC to obtain pure 11 (8.6 mg;
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Description of plasmid construction 
Fungal expression vectors 
FH-1. The 1.5 kbp promoter sequence of eqxS was amplified from FusWT genomic DNA with primer 
pair HygB2promoter-F / HygB2promoter-R. The eqxS NRPS sequence together with 500 bp downstream 
(terminator region) was amplified with primer pair vector2ACATR-F / vector2ACATR-R. Yeast 
recombination was used to construct FH-1 by transforming S. cerevisiae BY4741 with both PCR 
amplicons together with an 8 kbp NotI/BamHI fragment from pHygB-EqiACATR. 
FH-2. This vector was constructed in two parts. First, the sgfp sequence was amplified from gGFP with 
primer pair PmeI-sGFP-F / sGFP-R and cloned by yeast recombination into PmeI-linearized FH-1 to 
make plasmid pHygB-PmeI-sGFP. Then, the eqxR sequence together with the alcA promoter were 
amplified from the alcAeqxR plasmid 1. This amplicon was transformed into NotI-linearized pHygB-
PmeI-sGFP by yeast recombination to make plasmid FH-2.  
FH-3. To extend the eqxS promoter and include eqxC, PCR was used to amplify the sequence with primer 
pair deg3prom2-F / ER2vect-R from FusWT genomic DNA. This amplicon was cloned into NotI-
digested FH-1 by yeast recombination to form plasmid pHygB-ER+deg3ACATR. This plasmid was then 
cut with PmeI and joined with sGFP amplicon obtained from gGFP with primer pair PmeI-sGFP-F / 
sGFP-R by recombination in yeast to make plasmid pHygB-deg3ER+sGFP. FH-3 was constructed 
through yeast recombination of NotI-digested pHygB-deg3ER+sGFP with PCR product from alcAeqxR 
with primer pair TrpC2alcA-F / eqxR2eqxC.  
FH-4. The pyrG sequence was amplified from FusWT genomic DNA with primer pair pyrG2vect-F / 
pyrG2vect-R and joined with AscI- / NheI-linearized pHygB-deg3ER+sGFP by yeast recombination to 
make pPyrG-deg3ER+sGFP. This plasmid was then linearized with KpnI and recombined with PCR 
product amplified from alcAeqxR plasmid with primer pair pyrG2alcA-F/alcAg10517-R1 to make 
plasmid FH-4. 
Fungal expression plasmids 
hphgfp. The sGFP sequence was amplified from plasmid gGFP with primer pair sGFP-F / sGFP-R. The 
amplicon was fused with PmeI-linearized FH-1 via yeast-mediated recombination to afford plasmid 
hphgfp.  
hphCpas. The cpaS sequence was amplified from Aspergillus flavus AF293 genome by PCR with primer 
pair cpaS2deg3-F / cpaS2deg3-R. The amplicon was cloned into PmeI-linearized FH-1 by yeast 
recombination. 
hphCpasgfp. The cpaS sequence was amplified by PCR from A. flavus AF293 genomic DNA with primer 
pair cpaS2deg3-F / cpasFuLL2gfp-R and cloned into PmeI-linearized pHygB-PmeI-sGFP. 
hpheqxC+eqxSgfp. The eqxS coding sequence was amplified in two fragments. First the NRPS region 
was amplified with primer pair vector2ACATR-F/ eqxSNRPS-sGfP-R and cloned into FH-3. After 
linearizing the resultant plasmid with PmeI, the second fragment amplified with primer pair deg3vect_1f / 
deg3vect_2r was introduced.  
hphlovC+eqxSgfp. The lovC sequence was amplified from a yeast expression plasmid pMet25-lovC with 
primer pair lovC2eqxvect-F / lovC2eqxvect-R and subcloned into another plasmid. From this cloning 
plasmid, the lovC containing fragment was obtained by restriction digest. Together with the eqxR 




NotI-cut pHygB-PmeI-sGFP.  Into this resultant plasmid hphlovC+sGFP, the eqxS sequence was cloned 
as described above for the hpheqxC+eqxSgfp plasmid by yeast recombination. 
hpheqxC+lovBgfp. We amplified the coding sequence of lovB from YEpADH2p-LovB-His plasmid 
(from Tsai Lab, UCI) with primer pair deg3LovBPKS-F / LovB2GfP-R, and cloned it into PmeI-cut FH-3 
by yeast recombination. 
hphlovC+lovBgfp. The hphlovC+sGFP was linearized with PmeI and the lovB sequence introduced 
similarly to the hpheqxC+lovBgfp sequence above. 
pyrGprlC+prlS. This plasmid was constructed in two steps. First, the trans-ER, prlC was amplified from 
NRRL 50135 genomic DNA with primer pair g13602-F / g13602-R and cloned into NotI-digested FH-4 
by yeast recombination to make plasmid pyrGprlC+sGFP. Then, the new plasmid was linearized with 
PmeI and recombined with the prlS sequence amplified as two fragments with primer pairs g13593-F / 
g13593-1R and g13593-2F / g13593-R to make the final expression plasmid pyrGprlC+prlS. 
hphprlD. The prlD sequence was amplified from NRRL 50135 genomic DNA with primer pair 
NRRL_MT-F / NRRL_MT-R. This amplicon was cloned into PmeI-digested FH-2 to make the hphprlD 
plasmid. 
hpheqxD. The eqxD gene sequence was amplified from FusWT genomic DNA with primer pair 
deg3prom_eqxD-F / deg3prom_eqxD-R and cloned into PmeI-digested FH-2 to make the hpheqxD 
plasmid. 
Knockout plasmids 
ClusterPhleoKO. Initially, the eqxS PKS sequence was amplified with primer pair pRS2deg3PKS-F / 
pRS2deg3PKS-R and cloned into vector pRS316 by yeast recombination to make plasmid pRSdeg3PKS. 
The 12 kbp BlpI / BsrGI fragment of pRSdeg3PKS was fused with a 3.8 kbp ClaI / NdeI fragment from 
TOPO-PKSPhleoKO, which contains a phleomycin resistance marker, to make plasmid 
pRSdeg3PhleoKO. ClusterPhleoKO was then constructed by transforming BlpI-linearized 
pRSdeg3PhleoKO with MTKO2 amplicon1 into S. cerevisiae BY4741 to replace the 5’ PKS sequence of 
eqxS with a fragment of eqxD. 
pRSpyrGKO. The pyrG sequence was amplified in two fragments with primer pairs: PyrKO-XbaI-F / 
PyrKO-R, and PyrKO-F / PyrKO-XhoI-R. A randomly selected sequence, the first exon of lovC, was 
amplified with primer pair LovCexpress-F/LovCex1-R from the Aspergillus terreus genomic DNA. Yeast 
recombination was utilized to make the pRSpyrGKO by flanking the lovC sequence with the two pyrG 








Table S1: Plasmids used in this study 
Plasmid Source 
FH-1 This study 
FH-2 This study 
FH-3 This study 
FH-4 This study 
gGFP Fungal Genetic Stock Center 
hphgfp This study 
hphCpas This study 
hphCpasgfp This study 
pRSdeg3PKS This study 
pRSdeg3PhleoKO This study 
TOPO-PKSPhleoKO This study 
ClusterPhleoKO This study 
pRSpyrGKO This study 
hpheqxC+eqxSgfp This study 
hpheqxC+eqxS This study 
hphlovC+eqxSgfp This study 
hphlovC+lovBgfp This study 
hpheqxC+lovBgfp This study 
pyrGprlC+prlS This study 
hphprlD This study 
hpheqxD This study 
pHygB-EqiACATR Kakule T. B., et al.1 
pHygB-PmeI-sGFP This study 
hphlovC+sGFP This study 






Table S2: Primers used in this study. 


































































































Table S3: NMR data of 4 (right) compared to 3 (left) in methanol-d4. 
                                                                   
 Previously reported data for Compound 3 
1 Compound 4 
No. ?  13C ?   1H, multiplicity, J (Hz) ?  13C ?  1H, multiplicity, J (Hz) 
1 204.6, C 210.1  
2 51.5, C 54.7  
3 46.2, CH 3.46, br 50.5 2.68, br 
4 133.4, CH 5.15, m 132.0 5.12, m 
5 132.6, CH 5.41, m 131.5 5.44, m 
6 39.9, CH 1.86, m 39.7 1.79, m 
7 43.6, CH2 1.89, m; 0.89, m 43.3 1.84, m; 0.85, m 
8 34.8, CH 1.53, m 34.6 1.51, m 
9 36.9, CH2 1.77, m; 1.11, m 36.8 1.75, m; 1.06, m 
10 29.5, CH2 2.01, br; 1.08, br 28.3 1.74, br; 1.01, br 
11 41.3, CH 1.68, m 41.0 1.62, m 
12 14.2, CH3 1.45, s 16.9 1.23, s 
13 128.0, CH 5.37, m 128.2 5.44, m 
14 127.9, CH 5.26, m 127.6 5.38, m 
15 17.8, CH3 1.52, d, 5.7 18.1 1.59, d, 5.7 
16 23.0, CH3 0.94, d, 6.8 22.9 0.93, d, 6.8 
2' nda 169.2  
3' nd 46.4b 3.27b, d, 16; 3.58b, d, 16  
4' nd 173.2  
5' nd nd 56.0 4.5, dd 
6' 62.2, CH2 3.79,m; 3.74, m 62.9 3.93,dd; 3.83, dd 
and = not detected 


























Figure S3: FH-4 vector map 
?
Figure S4: Diagnostic PCR analysis for eqx knockout mutants. Colony PCR done on isolated mutants 
using primer pairs deg3KOScreen-F / deg3KOScreen-R and MTKOScreen-F / MTKOScreen-R1 to screen 
for absence of regions marked red and green, respectively. Lane labelled 1 is the FusWT control; 2 and 3 
denote mutant Fus?eqx5 (in duplicate); 4 and 5 denote mutant Fus?eqx8; and lane 6 is the ectopic 
integrant (resistant to both hygromycin and phleomycin). Fus?eqx5 was sequenced and selected for 





Figure S5: Alignment of Illumina sequencing reads of Fus?eqx5 against FusWT reference genome. As 
expected, no single read was present within the targeted deletion region. Coverage for the overlapping 
homologous regions in the knockout cassette was 3 times that for the rest of the genome which 




Figure S6: Diagnostic PCR analysis to screen for knockout of pyrG from mutant Fus?eqx5. Colony PCR 
done on transformed mutants that were isolated from 5-FOA containing medium with primer pair 
pyrGseq-F / pyrGseq-R. Homologous integrants (clones 8, 9, 10, and 11) show a 640 bp band shift from 








Figure S7: LC/MS and UV data of cAATrp 1. 
 
Figure S8: LC/MS and UV data of 5. 
 





Figure S10: LC/MS and UV data of 7. 
 




















































Figure S20: 1H NMR spectrum of 4 in dmso-d6. Inset are the 2D HSQC NMR spectra in dmso-d6 after 
overnight incubation in methanol-d4 (left), and after a 5 minute exchange in methanol (right). An increase 
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ABSTRACT: Three new decalin-type tetramic acid analogues,
pyrrolocins A (1), B (2), and C (3), were deﬁned as products of a
metabolic pathway from a fern endophyte, NRRL 50135, from
Papua New Guinea. NRRL 50135 initially produced 1 but ceased its
production before chemical or biological evaluation could be
completed. Upon transfer of the biosynthetic pathway to a model
host, 1−3 were produced. All three compounds are structurally
related to equisetin-type compounds, with 1 and 3 having a trans-
decalin ring system, while 2 has a cis-fused decalin. All were active
against Mycobacterium tuberculosis, with the trans-decalin analogues
1 and 3 exhibiting lower MICs than the cis-decalin analogue 2. Here
we report the isolation, structure elucidation, and antimycobacterial
activities of 1−3 from the recombinant expression as well as the
isolation of 1 from the wild-type fungus NRRL 50135.
Papua New Guinea is a hot spot for plant biodiversity,harboring an estimated 20 000 individual species of
vascular plants. An estimated 60% of these are endemic to
Papuasia, one of the highest rates of endemism in the world.1
Further, it is thought that most tropical plants contain multiple
endophytic fungi,2 providing an immense unexplored reservoir
of secondary metabolites.
As part of our International Cooperative Biodiversity Group
(ICBG) program, we screened extracts of endophytic fungi
isolated from Papua New Guinea terrestrial and marine sources
for antibacterial activities. A methanol extract of a phylogeneti-
cally novel strain (NRRL accession number 50135) isolated
from the stem of an Asplenium sp. fern growing in Watunou,
Milne Bay Province, Papua New Guinea, was identiﬁed as
selectively active against Gram-positive bacteria including
Mycobacterium tuberculosis H37Ra (ATCC 25177), Staph-
ylococcus aureus, Streptococcus pneumoniae, and Bacillus subtilis
ATCC6633. We employed an antimycobacterial bioassay-
guided isolation to obtain the TB-active metabolite pyrrolocin
A (1), a trans-fused decalin-containing tetramic acid analogue
related to equisetin.3 When NRRL 50135 stopped producing 1,
we used a recombinant expression platform4 to induce its
production. This heterologous expression platform successfully
produced 1, matching the initial molecular weight, UV, NMR,
and CD spectra, as well as two additional desmethyl analogues,
pyrrolocin B (2) and pyrrolocin C (3). The three compounds
have diﬀerent conﬁgurations in the decalin ring system, with 2
having the cis-fused decalin ring and 1 and 3 having the trans-
decalin conﬁguration. To our knowledge, this is the ﬁrst report
of both cis and trans conﬁgurations being isolated from a single
biological source and may be valuable in understanding the
biosynthesis of this group of tetramic acid analogues.
Furthermore, transplanting, or indeed rescuing, synthetic
pathways from one organism into more tractable backgrounds
unquestionably furthers drug discovery by magnifying the
number and amount of rare natural chemicals with potential
pharmacological activities, i.e., accessing dormant biosynthetic
potential with a concomitant increase in production. Skillful
manipulation of these pathways could theoretically also steer
biosynthesis of undesirable intermediates or end products to
pharmacologically desirable entities in quantities useful for
experimentation or production.
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Tetramic acids are characterized by the presence of a 2,4-
pyrrolidinedione moiety in their structures. Tetramic acids that
are related to equisetin are particularly important because of
their reported antimicrobial activities,3,5−9 HIV-1 integrase
inhibition,10,11 and microtubule assembly inhibition.12 The
mechanism of their antimicrobial activities has been purported
to be due to inhibition of SecA,13 inhibition of undecaprenyl
pyrophosphate synthase,14 and inhibition of the histidine kinase
WalK.15 Due to their biological activities, the biosynthesis of
this group of compounds and related polyketides was also the
subject of interest in several reviews.16−18
■ RESULTS AND DISCUSSION
Initially, growth of the fungus on semisolid media led to the
robust production of 1 at approximately 50 mg L−1. The
compound was puriﬁed on the basis of promising activity
against M. tuberculosis. The methanol extract from NRRL
50135 was puriﬁed using a preparative C18 column to isolate 1.
High-resolution ESIMS determined its molecular formula to be
C27H40NO5. The
13C NMR spectra (Table 1) showed 27
carbon signals, while its 1H NMR spectra presented ﬁve oleﬁnic
protons, ﬁve methyls, four methylenes, and six methines. The
carbon connectivities in the decalin ring and the oleﬁnic side
chain were established by COSY, HMBC, and HSQC. Their
association with equisetin-type tetramic acid was evident from a
review of literature data that showed that 1 is related to
phomasetin, with the addition of two carbons in the oleﬁnic
side chain and with the presence of an N-methyl group. In
order to establish the relative and absolute conﬁguration of 1
and evaluate its antimycobacterial activity, we fermented NRRL
50135 for additional material. Unfortunately, as is often
observed in secondary metabolites isolated from cultivated
microorganisms, NRRL 50135 ceased production of 1 before
completion of this work. In order to achieve production of 1,
we identiﬁed the biosynthetic locus for its production and
Table 1. 1H and 13C NMR Data for Compound 1 (400 and 100 MHz, respectively, δ in ppm), 2, and 3 (500 and 125 MHz,
respectively)
1a 2b 3a
pos δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz)
1 195.7, C 204.5, C 198.6,c C
2 48.8, C 52.5, C 49.0, C
2-Me 13.7, CH3 1.33, s 19.2, CH3 1.30, s 13.3, CH3 1.32, s
3 39.3, CH 1.57, br dd (10.2, 10.2) 38.4, CH 2.72, br d (10.2) 40.4, CH 1.57, m
4 27.7, CH2 1.89, m 24.6, CH2 1.38, m 27.5, CH2 1.93, m
1.00, m 1.45, m 1.00, m
5 35.4, CH2 1.70, m 36.6, CH2 1.67, m 35.4, CH2 1.71, m
1.00, m 0.87, dd (13.4, 12.6, 2.9) 1.00, m
6 32.7, CH 1.47, m 29.8, CH 1.40, d (5.3) 32.9, CH 1.49, m
6-Me 22.2, CH3 0.87, d (6.7) 23.2, CH3 0.81, d (6.5) 22.1, CH3 0.88, d (6.5)
7 42.0, CH2 1.77, m 38.4, CH2 1.56, d (14.0) 42.0, CH2 1.77, m
0.81, m 1.11, dt (12.3, 5.3) 0.82, dd (12.9, 11.7)
8 38.7, CH 1.77, m 36.7, CH 2.09, br s 38.7, CH 1.79, m
9 126.0, CH 5.18, s 126.8, CH 5.09, s 126.0, CH 5.19, s
10 130.9, C 133.7, C 131.6, C
10-Me 22.2, CH3 1.52, s 23.3, CH3 1.63, s 22.4, CH3 1.52, s
11 48.8, CH 3.14, m 43.5, CH 3.20, d (9.8) 48.4, CH 3.18, m
12 130.7, CH 5.21, dd (15.4, 9.8) 134.1, CH 5.50, dd (14.2, 10.5) 131.0, CH 5.21d
13 131.3, CH 5.69, dd (15.4, 10.4) 135.9, CH 6.04, dt (10, 3) 132.1, CH 5.72, dd (15.6, 10.0)
14 130.9, CH 5.86, dd, (15.4, 10.5) 136.1, CH 6.09, dt (10, 3) 131.4, CH 5.90, dd (15.0, 11.2)
15 129.5, CH 5.49, ddd, (15.4, 10, 7) 130.3, CH 5.63, pentet (7.5) 130.3, CH 5.51, dt (15.1, 7.0)
16 42.1, CH2 2.09, ddd (13.8, 7, 7) 42.1, CH2 2.24, pentet (6.4) 42.4, CH2 2.09, m
1.99, ddd (13.8, 7, 7) 2.18, pentet (6.4) 2.00, pentet (6.8)
17 65.6, CH 3.56, pentet (6.5) 68.7, CH 3.78, m 65.9, CH 3.59, m
18 22.7, CH3 0.98, d (6.5) 23.1, CH3 1.14, d (6.20) 23.1, CH3 0.98, d (6.1)
2′ 176.0,c C 180.8, C 179.2,c C
3′ 100.6,c C 100.0,c C 100.0,c C
4′ 190.6,c C 192.9, C 190.5, C
5′ 67.6, CH 3.77, m 62.4, CH 3.87, br s 63.3, CH 3.79, m
6′ 58.0, CH2 3.80, dd (12, 2) 64.3, CH2 3.83, dd (11.4, 3) 60.4, CH2 3.62, d (11.0)
3.68, dd, (12, 1.8) 3.77, m 3.57, dd (12.2, 5.9)
N-Me 26.8, CH3 2.93, s
aDMSO-d6.
bCD3OD.
cBroad signal. dOverlapped with H-9.
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moved it into the expression host, Fusarium heterosporum, as
reported elsewhere.4 In this context, the major compounds
produced were not those found in NRRL 50135, but instead
comprised approximately 800 mg of desmethyl pyrrolocin
analogues B (2) and C (3), along with a smaller amount of 1,
per kilogram of fermentation.
Compound 2, which was isolated as an oﬀ-white, amorphous
solid, was the major metabolite found in the extract. High-
resolution ESIMS determined its molecular formula to be
C26H38NO5. Likewise 3, which was also isolated as an oﬀ-white,
amorphous solid, has a molecular formula of C26H38NO5, as
established by high-resolution ESIMS. Comparison of the UV
spectra and 1H, 13C, COSY, HSQC, and HMBC data of 2 and
3 revealed that the two have the same carbon structure and that
they diﬀer only in their stereochemistry. Furthermore, the
HRESIMS and NMR data showed that 2 and 3 are the N-
desmethyl analogues of 1. However, the proton and carbon
chemical shift values of 1 were more similar to 3 than to 2
(Table 1).
Relative Conﬁguration of the Decalin Ring Moiety.
NMR data showed that compound 2 has a cis-fused decalin
structure. In the 1H NMR spectrum of 2, the decalin ring
junction signals H-3 (δ 2.72 ppm) and H-8 (δ 2.09 ppm) were
deshielded compared to the same protons in 1 and 3. This is
consistent with other cis-decalin tetramic acid analogues5,11,15
when compared to their trans-fused counterparts.3,6−8,10,14 The
NMR data also indicated that the fused cyclohexyl ring assumes
a chair conformation where H-3 is axial while H-8 is equatorial
(Figure 1). The absence of a diaxial coupling between these two
protons caused H-8 to be seen as a broad singlet in the 1H
NMR spectrum, while H-3 was seen as a broad doublet with J =
10.2 Hz due to its coupling with H-4ax (δ 1.38 ppm). The
ROESY spectrum of 2 also showed a correlation between H-3
and H-8, which conﬁrmed that the two are not in a diaxial
conﬁguration (Figure 1). H-3 was further observed to correlate
with H-5ax (δ 0.87 ppm) and H-7ax (δ 1.11 ppm), while H-8
was also seen to correlate with both H-7ax and H-7eq (δ 1.56
ppm). This was also the case with the equatorial C-6 methyl (δ
0.81 ppm), which exhibited same intensity ROESY correlations
with both H-7ax and H-7eq and with H-5ax and H-5eq (δ 1.67
ppm). On the other hand, H-6ax was seen to correlate with H-
4ax (δ 1.45 ppm), H-7eq, and H-5eq The fused cyclohexenyl ring
also seems to assume a pseudochair conﬁguration with H-3, C-
2 methyl, and H-8 in equatorial positions, which was deduced
from their ROESY correlations. Correlations were also
observed between H-4ax and H-12 since C-4 and C-12 are in
pseudoaxial positions. Likewise, the pseudoaxial H-9 (δ 5.09
ppm) also correlated with H-6ax.
The relative conﬁguration of 3 diﬀers from that of 2 at
stereocenters C-8 and C-11. The ﬁrst indication was the upﬁeld
shifts of the proton signals H-3 (δ 1.57 ppm) and H-8 (δ 1.79
ppm) as mentioned above. H-8 was also more deshielded than
H-3 compared to cis-fused decalins, where H-3 is more
deshielded.5,11,15 The ROESY spectrum established the relative
conﬁguration of 3 (Figure 2). The chair conformation of the
cyclohexyl ring was also deduced from the following ROESY
correlations: H-3 correlated with H-5ax (δ 1.71 ppm) and H-7ax
(δ 0.82 ppm); H-8 correlated with H-4ax (δ 1.00 ppm) and H-
6ax (δ 1.49 ppm). This therefore indicated that the C-6 methyl
is equatorial. The equatorial C-6 methyl also correlated equally
to H-5ax (δ 1.71 ppm) and H-5eq (δ 1.00 ppm) and to H-7eq (δ
1.77 ppm). The fused cyclohexenyl ring in 3 also seems to
adopt a pseudochair conﬁguration where H-3 and the C-2
methyl are anti to each other in pseudodiaxial positions. H-11
and C-10 methyl appeared to be in pseudoequatorial and
pseudoaxial positions, respectively, due to the observed
correlation between the C-10 methyl and C-2 methyl.
Absolute Conﬁguration: The Tetramic Acid Ring. The
absolute conﬁguration of C-5′ was determined by oxidative
bond cleavage of the tetramic ring followed by acid hydrolysis
(Figure 3).19 The crude extract containing both compounds 2
and 3 was reacted with sodium hypochlorite and sodium
hydroxide at room temperature for 8 h.19 The oxidation
products were extracted using ethyl acetate and evaporated in
vacuo. The residue was hydrolyzed using 6 M HCl for 15 h at
110 °C to yield serine. Marfey derivatization20 of the hydrolytic
product was performed using FDLA (1-ﬂuoro-2,4-dinitrophen-
yl-5-L-alanine amide). The resulting hydrolytic product serine-
FDLA (HPS-FDLA) was analyzed by analytical HPLC together
with reference standards L- and D-serine, which were derivatized
in the same way as the hydrolytic product serine. The HPS-
FDLA eluted at 25.00 min, while D-serine-FDLA injected alone
and L-serine-FDLA injected alone eluted at 24.83 and 24.63
min, respectively. The HPS-FLDA that was spiked with L-
serine-FDLA showed two peaks, at 24.54 and 24.99 min, while
the HPS-FDLA that was spiked with D-serine-FDLA showed
one peak, at 24.96 min. The HPS-FDLA was also analyzed by
LC-MS and showed the expected ion peak at m/z 339 [M +
H]+.
Figure 1. Relevant ROESY correlations in 2.
Figure 2. Relevant ROESY correlations in 3.
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Absolute Conﬁguration: The C-17 Hydroxy Group of
the Oleﬁnic Side Chain. Mosher derivatization was
performed on 2 and 3 separately. Each compound was reacted
with (R)- and (S)-MTPA chloride to form (S)-MTPA and (R)-
MTPA esters, respectively. 1H NMR analysis of the Mosher
esters was performed, and the ΔδS−R calculated (Figure 4).21
Both 2 and 3 were found to have the 17R conﬁguration.
Absolute Conﬁguration: The Decalin Ring of 2.
Without any derivatization step, the exciton CD method22
was used to elucidate the absolute conﬁguration of 2. This was
possible because two existing chromophores can possibly
interact and exhibit exciton split CD spectra, which can then be
observed as a positive or negative Cotton eﬀect. The positive
Cotton eﬀect that is predicted from the conﬁguration of the
two chromophores of 2 (Figure 5A) was observed in the
experimental CD spectra of 2 (Figure 5B). The tetramic acid
ring attached at C-2 and the conjugated diene attached at C-11
are two chromophores that coupled to cause the positive
Cotton eﬀect that was observed in the experimental CD
spectrum of 2. The absolute conﬁguration of 2 was therefore
assigned as 2R, 3S, 6S, 8S, 17R, and 5′R. This method has been
applied to establish the absolute conﬁguration of natural
products with pre-existing chromophores, including abscisic
acid, quassin, dendryphiellin F, and arnottin II.22
Absolute Conﬁguration: The Decalin Ring of 3. The
optical rotation [α]D = +130 and the CD spectrum of 3 (Figure
6) were almost identical to that of phomasetin ([α]D = +93.9)
and ent-equisetin (Table 2) and opposite of that of altersetin/
coniosetin (Figure 7).6,8 The C-5′R conﬁguration of the
tetramic ring as determined above is also consistent with that of
phomasetin. The absolute conﬁguration of 3 was therefore
assigned as 2R, 3S, 6S, 8R, 17S, and 5′R.
Absolute Conﬁguration of 1. Compound 1, which was
isolated as an oﬀ-white oil, was a minor compound in the
recombinant expression. Its HPLC retention time (Figure 8A
Figure 3. (a) Oxidative bond cleavage;17 (b) acid hydrolysis; (c) derivatization with Marfey’s reagent.
Figure 4. ΔδS−R values obtained in pyridine-d5 of the MTPA esters of
1 and 2.
Figure 5. (A) Expected Cotton eﬀect of 2 according to the exciton CD method of determining absolute conﬁguration. (B) Experimental CD
spectrum of 2.
Figure 6. Experimental CD spectrum of 3 in methanol.
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and B), high-resolution ESIMS, UV, 1H, 13C, COSY, HMBC,
and HSQC NMR spectra, and CD data matched those of 1
from the wild-type fungus NRRL 50135. Determination of the
absolute conﬁguration of 1 was achieved by comparison of its
ROESY and CD spectra with 3. The ROESY spectrum of 1 was
very similar to that of 3, which indicates that 1 and 3 have the
same relative conﬁguration. The similarity of the CD spectra of
these two compounds further revealed that 1 and 3 have the
same absolute conﬁguration.
Biosynthesis of Pyrrolocins and Related Compounds.
The co-occurrence of 1, 2, and 3 seems to suggest that 2 and 3
are cis- and trans-adducts originating from an intramolecular
Diels−Alder reaction in the biosynthetic process.16,17 Chemi-
cally, this reaction usually prefers to go through an endo
transition state, which leads to the cis-decalin isomer, while the
less favored exo transition state leads to the trans-decalin. In
secondary metabolism, the favored stereochemical route is
usually controlled by enzymes, rather than by solution
chemistry. For example, the fungal polyketide solanapyrone is
cyclized by a fairly novel enzyme after release of the
intermediate from the polyketide synthase (PKS).16,17 In a
more relevant example the fungal decalin lovastatin is produced
by a PKS that is similar to the pyrrolocin PKS. In lovastatin
biosynthesis, it is the PKS itself that controls decalin
stereochemistry, leading to strict production of the trans-
decalin. The relevant biosynthetic intermediate is proposed to
contain an ene that is activated by conjugation to an enzyme-
bound thioester. By contrast, the synthetic analogue of the
proposed intermediate leads to a mixture of cis- and trans-
decalin compounds, reﬂecting a mixture of endo- and exo-
Diels−Alder reactions, respectively.
Equisetin and its related compounds are thought to be
synthesized by a similar mechanism, wherein the PKS itself
would dictate whether the Diels−Alder reaction follows the
endo or exo pathway. In the present study, 1 was found as the
major product by NRRL 50135, and only trace amounts of 3
and none of 2 were detected (Figure 8A), revealing that only
trans-decalins were produced in the wild-type fungus. On the
other hand, the heterologous expression yielded 2 and 3 in a
∼2:1 ratio, which is what one would expect for a nonenzymatic
reaction (Figure 8B). Although there are many reasons for this,
the result implies that a separate Diels−Alderase domain might
be involved in the biosynthesis of equisetin-like compounds,
which in the present study might not be present in the
heterologous expression. As postulated by other authors,17 it
seems that LovB (the lovastatin nonaketide synthase) and EqxS
Table 2. CD Data of 3 and Related Tetramic Acid Analogues
compound CD λmax nm (Δε)
3 225 (+4.8) 232 (+6.5) 260 (+2.6) 288 (+7.5) 330 (0)
phomasetin10 225 (+3.2) 232 (+4.4) 260 (+1.0) 290 (+5.2) 330 (0)
ent-equisetin10 235 (+6.0) 250 (+4.0) 291 (+12.5) 330 (0)
equisetin10 227 (−5.5) 235 (−7.5) 260 (−3.0) 290 (−8.9) 330 (0)
altersetin6 212 (−2.9) 232 (−18.1) 253 (−5.0) 282 (−15.3) 330 (0)
coniosetin8 227 (−11.4) 232 (−12.0) 251 (−1.4) 283 (−3.0) 330 (0)
Figure 7. Experimental CD spectrum of coniosetin (reprinted with
permission from ref 8).
Figure 8. (A) HPLC chromatogram with PDA detection of the original extract of NRRL 50135. (B) HPLC chromatogram with PDA detector of the
extract from the expression platform in mutated F. heterosporum.
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(equisetin PKS-NRPS hybrid), at the very least, contain a
binding pocket to direct the stereochemical outcome of the
reaction. On the other hand, the direct product of the
pyrrolocin PKS still contains a carbonyl in the correct position
to activate an ene for the Diels−Alder reaction. By contrast, in
lovastatin biosynthesis, more advanced PKS intermediates no
longer contain an activated ene. This result implies that perhaps
pyrrolocins are enzymatically cyclized in the wild-type host, but
not in the recombinant host.
Of additional interest, despite the structural similarities
between pyrrolocins and compounds such as equisetin, these
compounds are often enantiomers of each other. While this fact
is very convenient in terms of assigning the absolute
conﬁguration of the compound series as we have done here,
it is curious. Why is the D-amino acid always found with one
decalin absolute conﬁguration and the L-amino acid with the
other? We propose two possibilities. First, the presence of the
D- or L-amino acid may be controlled enzymatically; the
conﬁguration would then dictate the stereochemical course of
the Diels−Alder reaction. Second, since the α position is
relatively labile in the tetramic acid motif, the amino acid may
begin as L-conﬁgured and equilibrate to the thermodynamically
favored conﬁguration based upon the stereochemistry of the
decalin ring. These ideas provide a testable hypothesis that will
enable understanding of the timing and biochemical basis of the
Diels−Alder reaction in pyrrolocins and the many structural
analogues.
Biological Activity. Compounds 1−3 were found to be
active against M. tuberculosis, with 1 and 3 being more potent
than 2 (Table 3). The data seem to indicate that a trans
conﬁguration and N-methylation enhance the potency of
antimicrobial activity.
■ EXPERIMENTAL SECTION
General Experimental Procedures. UV spectra were measured
on a Hewlett-Packard 8452A diode array spectrophotometer (Agilent,
Santa Clara, CA, USA). IR spectra were recorded using a JASCO
(Easton, MD, USA) FT/IR-400 spectrometer. Speciﬁc rotations were
recorded on a PerkinElmer (Downers Grove, IL, USA) 343 digital
polarimeter in MeOH at 22 °C. CD spectra were recorded on an Aviv
model 420 CD spectrometer (Aviv Biomedical, Inc., Lakewood, NJ,
USA) in methanol at 25 °C. NMR spectra were recorded on a Varian
(Palo Alto, CA, USA) INOVA at 500 MHz for 1H and 125 MHz for
13C using vendor-supplied pulse sequences.
Accurate mass measurements were performed by HRESIMS on a
Micromass Q-tof Micro (Waters, Milford, MA, USA) using positive
ion mode and an FTMS (LTQ-FT, ThermoFisher, Waltham, MA,
USA). HPLC was performed on an Agilent 1200 series equipped with
a PDA detector (Agilent Technologies). A Luna 5 μm C18 column,
250 × 10 mm (Phenomenex, Torrance, CA, USA), was used for the
isolation of the three compounds. Supelco Diaion HP20SS was
purchased from Sigma-Aldrich (St. Louis, MO, USA). TLC was
conducted using Kieselgel 60 F254 (Merck, Whitehouse Station, NJ,
USA).
Cultivation and Biological Source. The fern Asplenium sp. was
collected in Watunou, Milne Bay Province, Papua New Guinea, by a
team from Wyeth (now Pﬁzer). A piece of the stem was rigorously
surface-sterilized, and the sterile stem was placed on malt extract agar
containing antibacterials and 1 μg/mL cyclosporin until fungal hyphae
were observed to protrude from the stem. The strain was initially
isolated with the name ENDO-0549, and after axenic cultivation, it was
deposited in the NRRL culture collection as NRRL 50135.
Phylogenetic analysis using molecular markers identiﬁed NRRL
50135 as a potentially novel genus in the order Diaporthales. The
sequences were deposited in GenBank (KM107910).
Preparation of Inocolum of NRRL 50135. NRRL 50135 was
cultured on Difco potato dextrose agar. A 250 mL Erlenmeyer ﬂask
containing 50 mL of seed medium, Difco potato dextrose broth, was
inoculated with agar-grown culture. The seed was incubated at 22 °C
with shaking at 200 rpm until suﬃcient cell density was achieved to
inoculate the production fermentation.
Fermentation of NRRL 50135. The production fermentation
medium consisted of 15 g of nongauze milk-ﬁlter paper (KenAG
Animal Care Group, Ashland, OH, USA) cut into 8 mm wide by 60
mm long strips and 102 g of milled long grain white rice wetted with
125 mL of 0.1% yeast extract solution per 2.8 L Fernbach ﬂask. The
fermentation was inoculated with 20 mL of the seed and incubated
stationary at 22 °C for 15 days.
Isolation of 1 from NRRL 50135. The cells were extracted three
times with methanol (0.6 L). The combined extract was evaporated
under reduced pressure to dryness. The methanol extract was then
puriﬁed by reversed-phase HPLC using a C18 column (Phenomenex
Luna, 12 μp, 50 × 250 mm) and a gradient solvent of 85−100%
acetonitrile in water (40 mL/min, 0 min run), with both solvents
containing 0.01% in volume of triﬂuoroacetic acid (TFA). The peak at
18 min, monitored at 293 nm, was concentrated to give partially
puriﬁed pyrrolocin. The compound was further chromatographed by
HPLC using a diﬀerent column (YMC ODS-A, 10 μp, 30 × 250 mm)
and a gradient solvent of 80−100% acetonitrile in water (20 mL/min,
23 min run), with both solvents containing 0.01% in volume of TFA.
The peak at 17 min was collected and evaporated under reduced
pressure to aﬀord 1 as a colorless oil (7.2 mg).
Fermentation Procedure for F. heterosporum. Mutant strains
of F. heterosporum carrying pyrrolocin biosynthetic genes were
maintained and grown as described.4
Isolation of 1−3 from F. hereosporum. Three-week cultures of
F. heterosporum grown on 500 g of corn grit agar at room temperature
in 2.5 L Fernbach ﬂasks were extracted twice with acetone for 12 h.
Extracts were pooled and dried in vacuo using a rotary evaporator (IKA
Works, Inc., Wilmington, NC, USA) to aﬀord the crude extract. A
portion of the crude extract (6.7%) was dissolved in MeOH, mixed
with Diaion HP20SS, and dried. The resin was loaded into a column
(8.5 cm × 2.0 cm i.d.) and fractionated using 40 mL each of the
following solvents: 100% water, 75% H2O/25% 2-propanol, 50%
H2O/50% 2-propanol, 25% H2O/75% 2-propanol, and 100% MeOH
to yield ﬁve fractions, designated FW, F1, F2, F3, and F4.23 The
fractions were collected and solvents evaporated using a rotary
evaporator. Bioassay-guided fractionation showed anti-TB activity for
F3. F3 was puriﬁed by semipreparative HPLC using a reversed-phase
C18 column at a 3.5 mL/min ﬂow rate as follows: 60% ACN/20% 0.1%
aqueous TFA from 0 to 5 min, linear gradient from 60% to 100% ACN
from 5 to 20 min. Compound 1 (1.5 mg) eluted at 18.7 min, 2 (5.0
mg) at 16.0 min, and 3 (11.5 mg) at 13.0 min.
Preparation of (R)- and (S)-MTPA Ester Derivatives of 2 and
3.24 2 and 3 (0.5 mg each) were separately dissolved in pyridine-d6
(150 μL) and transferred into clean NMR tubes. Under a N2 gas
stream, (R)-(+)-α-methoxy-α-(triﬂuoromethyl)phenylacetyl chloride
(5 μL) was added into each sample, and the NMR tubes were then
carefully shaken to mix the samples and the MTPA chloride evenly.
The NMR tubes were allowed to stand at room temperature and
monitored every 2 h by 1H NMR. The reaction was found to be
complete after 6 h. 1H NMR data of the (S)-MTPA ester derivative of
2 (2a) (500 MHz, pyridine-d6, data were assigned on the basis of its
1H−1H COSY correlations): δ 0.81 (3H, d, J = 6.3 Hz, H3-6-Me), 1.21
(3H, s, H3-2-Me), 1.31 (3H, d, J = 6.3 Hz, H3-18), 2.44 (2H, m, H2-
16), 5.12 (1H, s, H-9). 1.64 (3H, s, H3-10-Me), 5.58 (1H, p, J = 7.3
Table 3. Antimycobacterial Activities of 1−3
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Hz, H-15), 5.68 (1H, dd, J = 14.7, 10.7 Hz, H-12), 6.11 (1H, dd, J =
14.7, 10.0 Hz, H-13), 6.20 (1H, dd, J = 10.0, 14.0 Hz, H-14). 1H NMR
data of the (S)-MTPA ester derivative of 3 (3a) (500 MHz, pyridine-
d6, data were assigned on the basis of its
1H−1H COSY correlations):
δ 0.81 (2H, d, J = 6.6 Hz, H3-6-Me), 1.17 (3H, d, J = 6.3 Hz, H3-18),
1.48 (3H, s, H3-2-Me), 2.22 (2H, m, H2-16), 3.31 (1H, m, H-11), 5.40
(1H, m, H-15), 5.58 (1H, m, H-12), 5.91 (1H, m, H-14), 6.13 (1H, m,
H-13).
In the manner described for 2a and 3a, 2 and 3 (0.5 mg each) were
separately dissolved in pyridine-d6 and reacted with (S)-(−)-α-
methoxy-α-(triﬂuoromethyl)phenylacetyl chloride (5 μL) in NMR
tubes at room temperature for 6 h to aﬀord the (R)-MTPA esters of 2
(2b) and 3 (3b). 1H NMR data of the (R)-MTPA ester derivative of
2b (500 MHz, pyridine-d6): δ 0.82 (1H, d, J = 6.4 Hz, H3-6-Me), 1.21
(3H, d, J = 6.4 Hz, H3-18), 1.25 (3H, s, H3-2-Me), 1.64 (3H, s, H3-10-
Me), 2.44 (2H, m, H2-16), 5.09 (1H, s, H-9), 5.60 (1H, p, J = 7.1 Hz,
H-15), 5.69 (1H, m, H-12), 6.04 (1H, dd, J = 10.7, 14.7 Hz, H-13),
6.22 (1H, dd, J = 10.6, 14.9 Hz, H-14). 1H NMR data of the (R)-
MTPA ester derivative of 3b (500 MHz, pyridine-d6, data were
assigned on the basis of its 1H−1H COSY correlations): δ 0.80 (3H, d,
J = 6.3 Hz, H3-6-Me), 1.10 (3H, d, J = 6.4 Hz, H3-18), 1.52 (3H, s, H3-
2-Me), 1.80 (3H, s, H3-10-Me), 2.22 (2H, m, H2-16), 3.39 (1H, m, H-
11), 5.45 (1H, m, H-15), 5.58 (1H, m, H-12), 5.96 (1H, m, H-14),
5.99 (1H, m, H-13).
Oxidative Bond Cleavage of the Tetramic Acid Ring.19 One
F. heterosporum sample lacked a methyltransferase and made only 2
and 3. The crude methanol extract was obtained and dried, and a
portion (0.2 g) was dissolved in methanol (6 mL). Then 1 M NaOH
(0.75 mL) was slowly added, followed by a NaOCl solution (available
chlorine 8.5−13.5%, 3.5 mL). The mixture was stirred at rt for 8 h.
Then, 1 M aqueous Na2SO2 (3 mL) was added, and the mixture was
neutralized by addition of 1 M HCl. After removal of the solvent, the
residue was diluted with H2O, and then the resulting mixture was
extracted with ethyl acetate. The organic layer was dried in vacuo. The
residue was dissolved in 6 N HCl (0.5 mL) and heated in a sealed
ampule vial at 110 °C for 15 h. The solvent was removed in vacuo. The
absolute stereochemistry of the resulting serine was determined by the
advanced Marfey method.20
The acid hydrolysate was dissolved in 1 mL H2O. To a 100 μL
aliquot were added 1% FDAA (1-ﬂuoro-2,4-dinitrophenyl-5-L-alanine
amide) in acetone (200 μL) and 40 μL of 1 N NaHCO3.The mixture
was heated at 40 °C for 1 h in a water bath. The vial was then cooled,
and 2 M HCl (20 μL) was added. This solution was analyzed by
analytical HPLC using the following method: 0 min 5% ACN/95%
aqueous TFA (0.1%), 0−2 min 5−25% ACN, 2−3 min 25% ACN, 3−
48 min 25−70% ACN, 48−50 min 70% ACN.
Antimycobacterial Assay. M. tuberculosis H37Ra growth
inhibition was quantiﬁed using the colorimetric 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay modiﬁed
from previously published methods.25 Plant extracts and control drugs
were dissolved in dimethyl sulfoxide (DMSO) to produce test stock
solutions, and DMSO served as a negative control. M. tuberculosis
cultures were dispensed in 200 μL of ADC (Remel, Lenexa, KS, USA)-
enriched 7H9 medium into 96-well culture clusters at 100 000 cells per
well. Then 1 μL of DMSO (control) or DMSO containing extract or
drug dilution was added in quadruplicate wells. After incubation for 4
days at 37 °C, 11 μL of sterile MTT (5 mg/mL in PBS) was added
and further incubated for 12 h. The insoluble formazan salt formed
was solubilized by the addition of 50 μL of a solubilization solution
(5% SDS w/v, 50% DMF v/v, 45% H2O v/v). A570 was measured
using a Multiskan FC plate reader (Fisher Scientiﬁc, Waltham, MA,
USA). All data were corrected against media-only blank wells by
subtracting media-only A570. The percent inhibition was calculated as
the fraction of the sum of the test wells over the sum of control wells
subtracted from 1 and multiplied by 100. The IC50 was determined
from the percent inhibition as the concentration of test material that
inhibited at least 50% of growth of the test organism.
Cytotoxicity Assay. The cytotoxicity assay utilized CEM-TART
cells obtained from the NIH AIDS Reagent Reference Program (NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH).26 Cells were
grown in complete RPMI 1640 in a jacketed incubator with 5% CO2 at
saturated humidity and at 37 °C. The assay used round-bottom 96-
well culture cluster plates. Compounds to be tested were added in
quadruplicate wells, while controls were as follows: solvent only
(DMSO) in 16 wells, of which 8 received media only (“media only”
blank) and 8 received 20 000 cells/well CEM-TART cells (positive
growth control). A further 8 wells received a decreasing amount of
doxorubicin in duplicate wells (4 concentrations) and CEM-TART
cells serving as positive cytotoxicity control. After 4 days of incubation
11 μL/well of 5 mg/mL MTT in PBS was added, followed by 2 h of
further incubation. Cells were pelleted by centrifugation, and the
medium in each cell was aspirated oﬀ using a vacuum aspirator.
DMSO (150 μL/well) was added to dissolve the insoluble formazan
salt. To completely dissolve the formazan precipitate, plates were
usually agitated for 5 min using a Fisher Scientiﬁc MS1 S7 plate shaker.
A570 was determined using a Scientiﬁc Multiskan FC (Fisher Scientiﬁc)
plate reader. The resulting data were processed with a specially made
Excel spreadsheet to calculate the percent inhibition as follows: the
average of the media-only blank was subtracted from all wells. The
average of the test wells for each compound was subtracted from the
average of the positive control wells and divided by the average of the
positive growth control, resulting in a fraction of control. To
determine the percent fraction of inhibition, the fraction of control
was subtracted from unity and multiplied by 100. The IC50 was
determined from the percent inhibition as the concentration of test
material that inhibited at least 50% of TART cell growth.
Pyrrolocin A (1): brownish oil; [α]22D +56.1 (c 0.03, MeOH); UV
(MeOH) λmax nm (log ε 244 (3.48), 295 (3.05); CD λmax nm (Δε)
239 (+5.82), 294 (+2.40); IR (NaCl disk) νmax 3317, 2946, 2832,
2161, 2012, 1977, 1679; 1H NMR (DMSO-d6, 400 MHz) and
13C
NMR (DMSO-d6, 100 MHz) see Table 1; HRESIMS m/z 458.2906
[M + H]+ (calculated for C27H40NO5 458.2906).
Pyrrolocin B (2): oﬀ-white solid; [α]22D −150 (c 0.025, MeOH);
UV (MeOH) λmax nm (log ε) 238 (4.4156), 286 (4.0263); CD λmax
nm (Δε 236 (−16.9), 283 (3.0); IR (NaCl disk) νmax 3325, 2945,
2834, 2362, 2340, 1683, 1653, 1456; 1H NMR (CD3OD, 500 MHz)
and 13C NMR (CD3OD, 125 MHz) see Table 1; HRESIMS m/z
444.2751 [M + H]+ (calculated for C26H38NO5 444.2750; Δ +0.2
ppm).
Pyrrolocin C (3): oﬀ-white solid; [α]22D +130 (c 0.025, MeOH); UV
(MeOH) λmax nm (log ε) 247 (4.4776), 286 (4.1049); CD λmax nm
(Δε) 232 (6.46), 288 (7.56); IR (NaCl disk) νmax 3300, 2945, 2916,
2868, 2843, 2155, 1678, 1575, 1453; 1H NMR (DMSO-d6, 500 MHz)
and 13C NMR (DMSO-d6, 125 MHz) see Table 1; HRESIMS m/z




1D and 2D NMR spectra for compounds 1−3 and HPLC
chromatograms of the FDLA derivatives are available as
Supporting Information. This material is available free of
charge via the Internet at http://pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
*Phone: 801 582 4547. Fax: 801 585 5111. E-mail: lbarrows@
pharm.utah.edu.
Present Address
#(R.C.J.) De La Salle Health Sciences Institute College of
Pharmacy, Congressional Ave., Dasmariňas, Cavite 4114,
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ABSTRACT: The programming of the fungal polyketide synthase (PKS) is quite complex, with a simple domain architecture
leading to elaborate products. An additional level of complexity has been found within PKS-based pathways where the PKS is
fused to a single module nonribosomal peptide synthetase (NRPS) to synthesize polyketides conjugated to amino acids. Here,
we sought to understand the communication between these modules that enable correct formation of polyketide-peptide hybrid
products. To do so, we fused together the genes that are responsible for forming ﬁve highly chemically diverse fungal natural
products in a total of 57 diﬀerent combinations, comprising 34 distinct module swaps. Gene fusions were formed with the idea of
testing the connection and compatibility of the PKS and NRPS modules mediated by the acyl carrier protein (ACP),
condensation (C) and ketoreductase (KR) domains. The resulting recombinant gene fusions were analyzed in a high-yielding
expression platform to avail six new compounds, including the ﬁrst successful fusion between a PKS and NRPS that make highly
divergent products, and four previously reported molecules. Our results show that C domains are highly selective for a subset of
substrates. We discovered that within the highly reducing (hr) PKS class, noncognate ACPs of closely related members
complement PKS function. We intercepted a pre-Diels−Alder intermediate in lovastatin synthesis for the ﬁrst time, shedding
light on this canonical fungal biochemical reaction. The results of these experiments provide a set of ground rules for the
successful engineering of hr-PKS and PKS-NRPS products in fungi.
■ INTRODUCTION
Fungal polyketide synthase (PKS)−nonribosomal peptide
synthetase (NRPS) hybrid proteins synthesize a diverse array
of biomedically and agriculturally important natural products.1,2
These include the prescribed anticholesterol drug lovastatin,
the biologically useful cytochalasins,3 compounds such as
macrocidins4 that are critical in fungal pathogenesis of plants,
and many other agents. The PKS-NRPS hybrid products are
among the most common bioactive compounds isolated from
ﬁlamentous fungi. The ﬁrst fungal PKS-NRPS to be
characterized was the fusarin C synthetase (FUSS),5 and
since that time many related genes have been identiﬁed. The
many known fungal PKS-NRPS genes are very similar to each
other, but their chemical products are not. It has thus been of
great interest to learn the biochemical rules governing product
formation and to exploit these rules in synthesizing new
derivatives via genetic engineering.6−8 However, success in
these endeavors has so far been quite limited.
Fungal PKS-NRPS products are produced via the action of
two modules. A single type I, highly reducing (hr) PKS module
acts iteratively to synthesize a complex polyketide core.1 In
fungi, iterative hr-PKS proteins exert exquisite control over
regiochemistry, synthesizing polyketides with variable reduction
at each acetate extension step despite using the same set of
reductase domains repeatedly.9 How each domain can
diﬀerentially recognize products of diﬀerent chain elongation
steps has remained a mystery. Some fungal iterative PKSs also
require auxiliary proteins. For example, several known decalin-
containing polyketides require the cooperation of the PKS and
an auxiliary enoyl reductase (ER).10−13 Upon completion of
synthesis of the acetate-derived chain on the PKS, the enzyme
bound intermediate is transferred to the NRPS module, at
which point an amino acid is appended to the compound.1,2
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The NRPS is responsible for selecting the amino acid,
synthesizing the peptide bond, and sometimes performing
other steps, such as Dieckmann cyclization to produce tetramic
acids. The complexity of the PKS-NRPS biosynthetic process is
exempliﬁed in Figure 1, showing the biogenesis of equisetin.
Many diﬀerent types of fungal polyketide-peptide hybrids
have been isolated. In the case of lovastatin and relatives, only a
fragment of the NRPS is present, and amino acids are not
loaded.10 The remaining NRPS domains are thought to be
responsible for potentially catalyzing a Diels−Alder reaction
that cyclizes the linear polyketide chain to produce decalins.6,10
Other products include the cyclopiazonic acid precursor,
cAATrp, which contains the shortest possible polyketide
chain fused as a tetramic acid to tryptophan (Figure 2).14
Prepseurotin is derived from a longer, partially reduced
polyketide fused to phenylalanine.15,16 Equisetin has a decalin
polyketide structure, like lovastatin, but is fused to serine as a
tetramic acid.11,17 Fusaridione A is a long, linear polyene fused
to tyrosine.11 Tenellin and desmethylbassianin are ring-
expanded tetramic acid derivatives; their biosynthetic genes
are among the best characterized fungal PKS-NRPSs.7,18−20
Many other classes of PKS-NRPS products are known.21
A key to combinatorializing fungal PKS-NRPS proteins
would thus be to hybridize PKS modules, producing diverse
acetate-derived scaﬀolds, with NRPS modules, activating
diverse amino acids. Indeed, this has been tried on three
occasions with mixed success.6−8 Two major domains are of
primary importance in successful fusions: the acyl carrier
protein (ACP) from the PKS module, and the peptide bond-
forming condensation (C) domain from the NRPS module. It
was anticipated that the C domain might exhibit some substrate
selectivity, where only certain polyketide products might be
acceptable in amide bond formation. The lynchpin was
Figure 1. Biogenesis of equisetin showing the complex programming of the PKS where domains on a single polypeptide are utilized iteratively to
synthesize the polyketide core. An acyl transferase (AT) domain selects the malonyl units, the ketosynthase (KS) catalyzes the decarboxylative
condensation, the C-methyltransferase (MT) performs α-C-methylations, the ketoreductase (KR) reduces keto groups to hydroxyls and the
dehydratase domain (DH) eliminates the hydroxyl groups to form oleﬁns, which are then reduced to single bonds by the trans ER EqxC. The
synthesized polyketide core is then transferred to the NRPS module, composed of the adenylation domain, which selects the amino acid that gets
loaded onto the thiolation domain (T). Conjugation of the polyketide with amino acid is catalyzed by the condensation (C) domain. The R domain
catalyzes a Dieckmann reaction to release the product as a tetramic acid, trichosetin.25,29,30 Further N-methylation by EqxD forms equisetin.11
Whether the Diels−Alder reaction occurs on-enzyme or after product release is still unknown (it has been drawn on-enzyme for clarity).
Figure 2. Structures of PKS-NRPS products showing the polyketide
chain synthesized by the PKS module (black), and the amino acid
appended by the NRPS (red). Dihydromonacolin L is not an amidated
product because its biosynthetic enzyme, LovB, possesses a truncated
NRPS module.
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considered to be the ACP. This small (∼70−100 amino acids)
but critical domain is covalently tethered to all PKS
intermediates and serves to ferry them between diﬀerent
catalytic sites in the PKS.9 The ACP protein itself must form
productive protein−protein interactions with the ﬁve or more
protein domains in the PKS. The ACP also must form a
protein−protein interaction with the C domain, which accepts
the incoming polyketide substrate for elongation. Any protein
fusions between NRPS and PKS modules therefore pose both a
substrate selectivity problem (C domain) and a protein
interaction problem (ACP domain).
The major goal of this project was to determine basic
programming rules that would enable successful fusion of
fungal PKS-NRPS proteins. The study was designed to
disentangle the protein−protein interaction and substrate
selectivity questions in this highly complex system. To do so,
we proposed the hypothesis that fungal ACP domains contain
speciﬁc sequence elements enabling interaction with PKS and
NRPS modules. A series of gene fusions were made using
diﬀerent PKS and NRPS proteins, exploring several types of
ACP interactions, with the goal of maintaining normal PKS
function and forging productive ACP/C domain interactions.
The resulting genes were expressed, and the chemical products
were analyzed. In the event, we delineated protein−protein
interaction rules and showed that fungal C domains are highly
substrate-selective. The secondary goal was to understand key
reactions catalyzed by PKS-NRPS proteins, such as the Diels−
Alder reaction that leads to decalin products. With the
exception of the Diels−Alder reaction, which in the case of
lovastatin is clearly catalyzed by the native C domain, we found
that fungal PKSs operate independently of NRPS modules and
make the products that are expected from the natural PKS-
NRPS proteins. Taken together, these experiments provide an
integrated view of the function and engineering potential of
fungal PKS-NRPS hybrids.
■ RESULTS
Experimental Design and Mutant Construction. To
diﬀerentiate the eﬀects of protein−protein interactions and C-
domain selectivity, we fused PKS and NRPS proteins at
diﬀerent points, using four diﬀerent types of ACP connections
(Figure 3). First, we left the PKS ACP intact, fusing it directly
with the second C domain. Second, we replaced the ACP with
the ACP natively fused to the acceptor NRPS. Third, we fused
the N-terminal region of the ACP from the PKS with the C-
terminal region of the ACP natively fused to the acceptor
NRPS. Previous studies with PKS and NRPS proteins have
shown that diﬀerent regions of the ACP are responsible for
interacting with donor and acceptor modules.22,23 While this
has not been studied in fungi, we reasoned that a hybrid ACP
might overcome potential problems with donor or acceptor
recognition. At the least, it would provide crucial information
about fungal ACP function. Finally, since multiple ACPs are
functional in some bacterial pathways,24 we placed the ACPs
from the PKS and NRPS in tandem.
Fusions were performed by yeast recombination to generate
expression vectors. The fused genes were then expressed in a
model platform recently developed in Fusarium heterosporum.25
The strength of this platform is that it synthesizes heterologous
polyketides and polyketide-peptide hybrids in yields of ∼100−
1000 mg kg−1. We expected that some fusions might lead to
decreased yields of products, and therefore, this high yielding
starting point would enable even relatively poorly functioning
hybrids to be accurately analyzed. This platform uses the native
promoters and regulatory elements that normally produce
equisetin, but instead redirects them to the production of
heterologous products. We used the recently characterized
equisetin synthetase EqxS and fusaridione synthetase FsdS
proteins as the NRPS modules in all experiments.11,25 These
were then fused to PKS modules from eqxS and fsdS, as well as
from cyclopiazonic acid synthesis (cpaS),26 pseurotin synthesis
(psoA),15 and lovastastin synthesis (lovB).12 Where auxiliary ER
proteins were required by the PKS, these were coexpressed in
F. heterosporum. A total of eight PKS-NRPS fusions were
created, each with four diﬀerent ACP connections, for a total of
32 recombinant clones expressed in F. heterosporum. Of
particular importance, the function of the nonhybridized
(wild-type) PKS-NRPS proteins was ﬁrst assessed in F.
heterosporum, showing that all of the proteins were functional
prior to hybridization.11,25
The equisetin and fusaridione synthetases eqxS/eqxC and
fsdS were cloned from F. heterosporum, the same strain used as
the heterologous production line in this study. cpaS, psoA, and
lovB and lovC (a trans-ER) were cloned from Aspergillus f lavus,
A. fumigatus, and A. terreus respectively. Three of the fusion
types (comprising 12 total recombinants) failed to function,
including cpaS-eqxS, cpaS-fsdS, and lovB-fsdS. An absence of
products in these experiments could occur for several diﬀerent
reasons. For example, the polyketide product of cpaS is simply
acetoacetate, which may not be detectable in the experimental
conditions, or protein folding problems may occur. Because of
these and other reasons, it is not possible to deﬁnitively
conclude that absence of product is meaningful in terms of
protein interactions or substrate acceptability. Therefore, these
failed fusions will not be further analyzed. For the remaining
ﬁve fusion types (20 total recombinants), including eqxS-fsdS,
fsdS-eqxS, psoA-fsdS, psoA-eqxS, and lovB-eqxS, products were
detected (Figure 4).
In addition to these 32 mutants, we also constructed other
hybrids to answer speciﬁc questions resulting from these initial
studies, as described below.
ACP-PKS Interactions. All PKSs were active in making
polyketides when fused to their own ACP domains, but only a
subset of fusions between a PKS and a noncognate ACP led to
polyketide products (Figure 4). All four ACP combinations
eﬀectively led to the native PKS products in the reciprocal
crosses, eqxS-fsdS and fsdS-eqxS. This indicated that these ACPs
recognized all domains of each other’s PKS module. Modest
Figure 3. Design of gene fusions representing the diﬀerent
arrangements of the ACPs with the C domain. pksnrps1 (blue)
represents psoA, cpaS, lovB, eqxS or fsdS; and pksnrps2 (red)
represents eqxS or fsdS.
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and potentially insigniﬁcant yield diﬀerences were the only
observed eﬀects of swapping ACPs between these systems.
By contrast, in the case of pseurotin fusions psoA-eqxS and
psoA-fsdS, only the cognate ACPs were functional, and neither
the fusaridione ACP nor the equisetin ACP could substitute for
the pseurotin ACP (Supporting Information Figure S1).
Fusions containing either the pseurotin ACP alone, or the
tandem ACP system containing one ACP from pseurotin and
one from fusaridione or equisetin, both led to PKS product 5
(Figure 4). By contrast, no products were detected in the
hybrid ACP or noncognate ACP fusions. Compound 5 contains
the complete PKS chain in the correct reduction state as found
in prepseurotin. It was likely spontaneously cleaved from the
enzyme as the pyrone, as has been proposed for similar
products from fungal hr-PKS.12
lovB-eqxS fusions also led to PKS products, which diﬀered
depending upon which ACP combination was used. Previously,
when lovB was expressed intact in F. heterosporum,25 in addition
to a large amount of the expected product, dihydromonacolin L
(Figure 2), we obtained a small amount of pyrone 4 (Figure 4).
The cognate lovB ACP led to a PKS product 1 that was most
similar to the native monacolin product, but lacking Diels−
Alder cyclization (Figure 4; Supporting Information Figure
S2A). In addition, two pyrone shunt products 3 and 4 were
identiﬁed, as found with the wild-type enzyme when expressed
in F. heterosporum. Only these shunt products were observed
when noncognate ACPs were used, including from the hybrid
Figure 4. Summary of compounds identiﬁed from the diﬀerent PKS/NRPS fusions. 1, 2, 5, 6 and 7 are new compounds (nd = no new metabolites
detected in comparison to gfp-expressing control). Note: Compound 1, all double bonds are trans.
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ACP and equisetin-derived ACP fusions. Most interestingly,
when eqxS provided the ACP, the product was not reduced by
the trans-ER lovC. The best explanation for this observation is
that the equisetin ACP cannot interact with LovC. An
exhaustive search for new nitrogen-containing metabolites led
to the isolation of a minor product 2, a linear lovastatin-like
polyketide precursor modiﬁed by N-acetyl cysteine (biochemi-
cally analogous to the very similar leukotriene modiﬁcation27).
This same product was produced when the ACPs were placed
in tandem.
Transfer of PKS Products to the NRPS. Although 16 out
of the 32 gene fusions led to functional PKS proteins with
detectable products, only 4 of these led to products that were
clearly passed along to the NRPS module. These were the eqxS-
fsdS fusions, in which the expected product was clearly obtained
(Figure 4; Supporting Information Figure S3). The sole
recombinant natural product, eqxTyr 7, isolated from this
system included the decalin made by the equisetin PKS and the
tyrosine tetramic acid made by the fusaridione NRPS. All four
eqxS-fsdS fusions led to the same product. This indicated that
the fsdS C domain could accept the equisetin polyketide
product and could make functional contacts with the equisetin
ACP.
In the reciprocal fusion, fsdS-eqxS, the native fusaridione
polyketide was isolated, but it was not fused to serine from eqxS
and was instead decarboxylated. Interestingly, all four ACP
fusions led to the same product 6 (Figure 4; Supporting
Information Figure S4). This indicated that the eqxS C domain
could not accept polyketide products synthesized by fsdS, since
the native eqxS ACP was present in some fusions, precluding a
role for protein−protein interactions in governing C-domain
selectivity. Both the fsdS and eqxS ACPs could act in concert
with the PKS domains, leading to synthesis of the normal fsdS
PKS product. Decarboxylation of β-ketoacids is a spontaneous
reaction, so that 6 represents exactly what one would expect
from a functional PKS.
Similarly, pseurotin and lovastatin fusions led only to PKS
products, with no evident transfer to the fsdS or eqxS NRPS
modules. In the case of the lovastatin fusions, products were
still obtained with the construct containing the eqxS ACP alone,
implicating substrate selectivity of the C domain as the major
factor limiting transfer.
Diels−Alder Reaction in Lovastatin Biosynthesis. As
noted above, the lovB-eqxS fusion led to a polyketide product 1
resembling a pre-Diels−Alder product. Natively, lovB includes
not just the PKS module, but also an intact C domain and a
short piece of the adenylation (A) domain that activates amino
acids.10,12 Previously, it has been speculated that the lovB C
domain was responsible for Diels−Alderase activity.6,10,28 This
previous idea is strongly supported by the chemistry discovered
here, the ﬁrst time in which the pre-Diels−Alder product has
been observed as a lovB PKS product. To further probe this
issue, we fused lovB with fsdS at the position in which the lovB
A domain is fragmented. This construct was expressed in
tandem with lovC, and it yielded the lovastatin precursor,
dihydromonacolin L (Supporting Information Figure S5).
Thus, fusions with an intact lovB C domain yield the Diels−
Alder product, while fusions to heterologous C domains do not
and in some cases lead to pre-Diels−Alder products. This
provides strong evidence supporting the C domain as the
region responsible for the Diels−Alder reaction.
Of note, in the case of equisetin and other tetramic acids, the
tetramic acid motif remains adjacent to the decalin ring system,
in the perfect position to accelerate a Diels−Alder reaction. By
contrast, in lovastatin the ﬁnal PKS intermediate is chain
extended so that a methylene group is adjacent to the decalin
ring. Thus, chemically, it is highly likely that the decalin ring in
lovastatin must be formed at a chain length in which the
enzyme-bound thioester is immediately adjacent to the nascent
decalin; it is formed while still bound to the PKS. By contrast,
in principle the equisetin decalin ring could still be formed after
cleavage from the NRPS. Indeed, in a previous study, we found
evidence that the decalin rings in the tetramic acid pyrrolocin
may be formed post-PKS.25 Based upon these results and the
ideas of Hutchinson, Vederas, Tang, and others,6,10,12,28 we
speculate that the substrate selectivity and chemical recognition
inherent to C domains has been redirected to template the
Diels−Alder reaction in lovastatin synthesis.
C Domain Selectivity and KR Domain Activity. In
previous studies, the ketoreductase (KR) domain was shown to
control chain length in some fungal PKS-NRPS proteins.7 This
provided us with an opportunity to more ﬁnely investigate the
role of C domain in substrate selectivity, removing protein−
protein recognition from consideration and focusing solely on
the chain length presented to C domain. We swapped the eqxS
KR domain for the lovB KR domain, in the context of the full-
length eqxS PKS-NRPS (Figure 5). Since LovB and EqxS
natively synthesize nonaketides and octaketides respectively, it
was envisioned that slightly diﬀerent products would be
presented to C domain. When this chimera was coexpressed
with the trans-ER eqxC, several new metabolites were detected.
The major product was characterized to be the polyketide 8
Figure 5. Analysis of chimeric eqxS PKS with lovB KR. (A) The eqxS
KR was swapped for the LovB KR domain (green) in eqxS (i), and in
eqxS-fsdS (ACP1-to-Cond2; (ii)). HPLC-DAD analysis of crude
extracts of CGA cultures of FusΔeqx5 cotransformed with eqxC and
either (i) or (ii) shows the production of 8. Trichosetin and 7 are
synthesized in minor amounts by (i) and (ii), respectively. (B)
Comparison of 8 with the equisetin polyketide core and trichosetin
showing the position of the β-hydroxyl group.
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which is not conjugated to serine (Figure 5A). To our surprise,
8 was the same length as the equisetin pre-Diels−Alder
polyketide chain, but with a β-hydroxyl group in place of the
keto moiety (Figure 5B). A very minor amount of trichosetin,
normally the major product of eqxS + eqxC, was observed. In
contrast to expectation, eqxC cooperated with the chimeric
protein to perform the two normal reductions observed in
equisetin synthesis.
Similarly, a fusion was made in which the lovB KR was
swapped into the eqxS-fsdS chimera. The same major pre-
Diels−Alder compound 8 was again observed, with a very
minor amount of 7, the tyrosine analog of equisetin (Figure 5).
Both KR swaps provided the same result: simple reduction of
the β-keto group absolutely abolished transfer to the NRPS
module. Only a small amount of product, escaping the kinetic
reduction of the β-keto group, was captured by the equisetin
and fusaridione NRPS domain and added to an amino acid.
These results serve to strongly reinforce the role of C domain
in selecting the precise substrate for chain elongation.
Potential Impact of R Domain on Selectivity. The R
domains at the C-terminus of eqxS and fsdS belong to a subset
of proteins that catalyze Dieckmann cyclization to aﬀord
tetramic acids; they are not competent reductases and do not
bind to NAD(P)H.29,30 Previously, biochemical experiments
with FsdS R and ATR domains showed that, in the case of
FsdS, R has broad substrate selectivity that would not be
expected to impact the experiments described here.30 For
example, acetoacetyl-alanine was readily accepted by the
domains in vitro. To further probe this issue, we examined
the products of lovB-eqxS and cpaS-eqxS fusions, in which the
terminal R domain was covalently linked to green ﬂuorescent
protein (sGFP). In previous work with full length eqxS, we
showed that introduction of sGFP in this position blocked
activity of R, so that hydrolytic products were obtained instead
of Dieckmann cyclase products.25 The fusion products of lovB-
eqxS-sGFP were identical to those from lovB-eqxS, and as in the
previous experiments no products were detected from cpaS-
eqxS-sGFP. This experiment provides further evidence that the
primary chemical selectivity for the eqxS NRPS is likely to be at
the C domain.
■ DISCUSSION
Here, we answer some of the key unsolved questions about the
function and engineering of fungal PKS-NRPS hybrids. In total,
we synthesized and tested 57 fusion products, including 32
PKS-NRPS module swaps, 2 KR swaps, 1 lovB C-A fusion, and
22 GFP fusions to the PKS-NRPS hybrids. By analyzing the
chemical products resulting from these fusions, we tested the
hypothesis of ACP domain speciﬁcity, revealing speciﬁcity
Figure 6. A phylogenetic analysis of ACPs from hrPKSs, PKS-NRPSs, and lovB-type PKSs (with truncated NRPS). Starred ACPs were investigated
in this study. The eqxS ACP and fsdS ACP are more closely related to each other than they are to psoA, cpaS, and lovB ACPs.
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elements that will be essential in engineering. We showed that
the eqxS and fsdS C domains are highly substrate selective. Our
secondary goal was to better understand fungal hr-PKS
function. We provide new insights about the role of speciﬁc
domains in determination of Diels−Alderase activity and chain-
length determination. More fundamentally, we show that the
PKS module alone is suﬃcient to provide the expected
polyketide structure, and that C domain does not contribute
beyond the Diels−Alder reaction. We demonstrate for the ﬁrst
time a new product resulting from a functional in cis fusion
between complete PKS and NRPS modules. The ﬁrst pre-
Diels−Alder lovastatin enzymatic products were discovered,
which in tandem with other evidence provide strong support
for the role of C domain in lovastatin Diels−Alder reaction.
The biochemical basis of the Diels−Alder reaction has been
the source of great interest for the past 15 years, but it has not
yet been completely resolved. Elegant work by Vederas and co-
workers showed that LovB catalyzes the on-enzyme, stereo-
speciﬁc Diels−Alder reaction to form the decalin ring found in
the lovastatin precursor, dihydromonacolin L.28 Later studies
reported the inability of a truncated LovB, lacking the C
domain, to form monacolins when coexpressed with LovC, but
instead truncated pyrones are formed.10 The LovB C domain
was however able to restore monacolin production when added
in trans to the truncated LovB in vitro. Another study
demonstrated that LovB fused post-C domain with the
chaetoglobosin A synthetase (CheA) was capable of synthesiz-
ing dihydromonacolin L, whereas the direct fusion of the lovB
PKS with CheA C domain was nonproductive.6
In some ways, our results here are quite similar to the latter
two studies. We found that, in the absence of the native C
domain, LovB synthesizes polyunsaturated pyrones. When the
intact LovB C and a small part of LovB A are added back,
rather than tetramate formation, dihydromonacolin L is found.
The major diﬀerence is that, for the ﬁrst time, we have also
identiﬁed a pre-Diels−Alder product 1 from fermentations with
LovB lacking its native C domain. The isolation of 1 provides
direct evidence showing concretely that all of the domains in
LovB and LovC are functional, and that they synthesize an
intermediate that would be cyclized if a functional Diels−
Alderase were present. When that Diels−Alderase (C domain)
is added back, the Diels−Alder reaction takes place. This
evidence strongly favors the C domain hypothesis forwarded
previously by other researchers. We were able to isolate and
characterize this product because we designed our study to use
an expression platform that natively produces a high yield of
recombinant products.25
We thoroughly deﬁne the role of the ACP in governing PKS
function. In pairing PKS domains with noncognate ACPs, we
were ﬁrst faced with the question of whether PKS domains,
including the trans ER, would interact with the noncognate
ACP to form the native PKS polyketide intermediate to present
to the C domain. This question has been explored in several
other types of PKS proteins,22,31,32 but never before within the
fungal hr-PKSs. Within the fungal hr-PKS and PKS-NRPS
proteins, the role of ACP has been previously indirectly tested
in a series of domain fusions within the closely related bassianin
and tenellin PKSs.7 In these fusions, the tenellin ACP was
always in place, and it could interact with several other domains
from the bassianin PKS. Our work explicitly and thoroughly
explores the role of ACP in PKS interactions. The eqxS ACP
and fsdS ACP are equivalent and interchangeable. The lovB-
eqxS fusions reveal that the eqxS ACP can interact with the
LovB PKS, but does not interact with LovC. Interactions with
LovC are restored by reintroducing a portion of the lovB ACP
in the hybrid ACP fusion. By contrast, the eqxS and fsdS ACPs
are incapable of interacting with the psoA PKS domains.
A phylogenetic analysis of the ACPs (Figure 6) illuminates
the mixed results from these ACP-PKS interaction studies.
Strikingly, more closely related ACPs are interchangeable, while
more distantly related ACPs are not. The intermediate case,
involving the lovB swaps, provides an intermediate level of
transferability. Therefore, for swaps involving the use of
noncognate ACPs, source modules with closely related ACPs
may result in production of predicted PKS intermediates.
Transfer of polyketide intermediates to NRPS modules has
also been investigated in several cases. Within the fungal
enzymes, only three other studies have investigated the
compatibility of PKSs with noncognate NRPS modules. (1)
The aspyridone synthetase (ApdA) PKS module and the CpaS
NRPS module were expressed as separate proteins in
Saccharomyces cerevisiae.8 This in trans experiment led to
successful production of a small amount of the predicted
tetraketide-derived tetramate, whereas natively a diketide
intermediate is accepted by the CpaS NRPS module. The
ApdA PKS was shown to have the potential to synthesize
longer polyketide intermediates, but only the tetraketide was
captured by both the ApdA and CpaS C domains. (2) Highly
similar proteins desmethylbassianin synthetase DmbS and
tenellin synthetase TenS (>85% protein sequence identity)
were fused, leading to a successful synthesis of similar
products.7,20 These proteins synthesized hexaketide and
pentaketide tetramates with slightly diﬀerent methylation
patterns. (3) The lovB PKS was fused to the CheA NRPS,
but no products were detected.6 The incompatibility of LovB
PKS with CheA NRPS was attributed to an early evolutionary
divergence between the LovB-type PKSs and other PKS-NRPSs
as observed from phylogenetic analyses.
A complicating factor in the above studies was that they did
not diﬀerentiate between the impact of protein−protein and
substrate selectivity interactions between modules, and they
used only single swaps rather than thoroughly investigating
multiple combinations. Here, we tested the eﬀect of C domain
selectivity independent of potential unfavorable ACP inter-
actions for a larger set of PKS/NRPS pairings that diﬀer
signiﬁcantly in sequence similarity. In the context of previous
work by others, our thorough data here demonstrates that C
domains of PKS-NRPS enzymes are often highly chemo-
selective. The lovB-eqxS fusions synthesize several nonamidated
polyketide chains. Even in the presence of the eqxS ACP which
forms interactions with eqxS C domain, the polyketides are not
transferred to the NRPS. These cases imply an underlying strict
eqxS C domain substrate selectivity beyond the presence of
productive ACP interactions. This is further supported by the
inability of similar fsdS-eqxS fusions to synthesize tetramate
products, but instead form the polyketide 6. In fact, the
experiment with the lovB KR domain swap suggests that the
eqxS C domain possesses a high selectivity for only the
equisetin polyketide core because even when it is the
disfavored/aberrant polyketide intermediate among others,
trichosetin is the only amidated product detected. On the
other hand, the fsdS C domain displays more relaxed substrate
selectivity, accepting the equisetin polyketide core in addition
to the more rigid polyene polyketide chain found in fusaridione.
In these eqxS-fsdS expressions, many other nontetramate
products are detected; it is therefore intriguing that eqxTyr 7
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is the only amidated product observed. One explanation for this
is that the fsdS C domain is not truly accepting of broad
substrates, but rather selects for particular attributes of the
substrate which may include length, degree of unsaturation
and/or methylation pattern. This becomes more apparent
when the octaketide intermediate of equisetin is compared to
the heptaketide polyketide product of fsdS PKS. It is possible
that fsdS C accepts the linear pre-Diels−Alderase intermediate.
The pseudorelaxed selectivity of the fsdS C domain for the
equisetin core is further demonstrated in the lovB KR swap
experiment, where trace amounts of eqxTyr were detected,
when the equisetin polyketide core is produced as an aberrant
product among others. Tenellin synthetase (TenS) produces
several tetramates in the absence of its trans ER.20 Upon the
basis of this result, C domains have been speculated to be broad
substrate, but our data shows that this is not universal. Even for
TenS, the polyketide chains did not diﬀer signiﬁcantly among
the tetramates synthesized; the lengths of these chains are
within one ketide unit of the native substrate of the C domain.
This diﬀerence is exactly what we found for the successful chain
transfer in eqxS-fsdS fusions.
Our studies also enabled other interesting observations into
PKS domain function when the eqxS KR was swapped for the
lovB KR. The synthesis of the same equisetin core polyketide
chain albeit with a β-hydroxyl group instead of the anticipated
nonaketide chain, in constrast with previous work,7 shows that
iterative PKS programming is much more complex and each
system should be evaluated individually until more universal
rules can be discovered. The chain length factor for eqxS
probably lies with the KS domain. This result also shows that,
for the case of eqxS biosynthesis, capture of the polyketide
intermediate by the C domain occurs after polyketide
elongation is complete. KR and C domain compete with each
other for the last intermediate in chain elongation, with the KR
reaction dominating. A caveat in interpreting this result is that
the β-hydroxyamide would not be a substrate for Dieckmann
cyclization, so that later hydrolysis of the amide bond would
provide the detected product even though successful chain
transfer had in fact occurred. Arguing against this possibility is
the fact that we have previously isolated non-Dieckmann
products from experiments with both FsdS and EqxS, and they
were perfectly metabolically stable.11,25
The results of this study, adding to previous work, will be
useful in the engineering of fungal polyketides and polyketide-
peptide hybrids. First, the work shows that the expected
polyketide products themselves can be directly formed via
expression of these fusions; merely swapping out C domains
can provide valuable products. Second, it shows that successful
engineering strategies will require appropriate selection of
ACPs. Currently, it is clear from this work and previous studies
that phylogenetically closely related ACPs are empirically likely
to function in a heterologous context. However, more research
is required to delineate exactly the recognition factors between
ACPs and these complex enzymes that may facilitate rational
swaps between PKSs. Finally, the substrate selectivity of C
domains is a serious hurdle in the generation of recombinant
products. The best way forward at this point will involve using
C domains that accept somewhat similar PKS products, but
that append diﬀerent amino acids to the compound. The value
of this approach is clearly shown by the very conservative
previous successes in synthesizing bassianin and cyclopiazonic
acid derivatives and in our case of switching the amino acid on
equisetin from serine to tyrosine. Fortunately, fungal PKS-
NRPS genes are ubiquitous,33 so that an enormous biodiversity
is available for such engineering eﬀorts.
■ METHODS
Cloning of Fungal Expression Plasmids. Generally, genes were
ampliﬁed from genomic DNA or subcloned coding sequences using
the high-ﬁdelity Phusion polymerase (NEB), and cloned into the
expression vectors by yeast recombination.34,35 Plasmid selection and
ampliﬁcation was then done in Escherichia coli. Details of plasmid
construction are contained in Supporting Information. Alignments and
phylogenetic analysis were generated with ClustalX.
Fungal Transformation. Fusarium heterosporum FusΔeqx5 and
FusΔeqx5pyrG10 were used as the expression hosts.25 The plasmids
were linearized with PacI/AscI prior to transformation into FusΔeqx5
as previously described.11,25 Selection was done with hygromycin 150
μg mL−1, and isolated transformants cultivated in potato dextrose
broth (PDB) 250 mL for 7 d at 30 °C and corn grit agar (CGA) 50 g
for 21 d at rt. psoA-eqxS and psoA-fsdS mutants were cultured in PDB
supplemented with sodium propionate (20 mM) at the 24-h point of
the culture because propionyl CoA is the ﬁrst unit loaded by PsoA.15
Absent addition of propionate, no new compounds were observed in
the psoA expressions.
General Procedures for Extraction, Puriﬁcation, and Char-
acterization of Compounds. PDB cultures were extracted with an
equal volume of ethyl acetate, and solvent removed under a vacuum.
The crude extracts were analyzed by HPLC using a Hitachi LaChrom
Elite instrument equipped with a diode array detector over a
Phenomenex Luna C18 column (4.6 × 250 mm, 5 μm). Preparative
HPLC was done using the Discovery HS C18 column (25 cm × 10
mm, 5 μm). Extracts were further characterized by LC/MS using the
Agilent ZQ to screen for new metabolites. Cultures on CGA were
extracted with acetone and the crude extracts treated similarly.
Compounds were generally puriﬁed by ﬁrst performing ﬂash
chromatography on end-plugged C18 using a methanol/water
gradient. The fractions containing the target compounds were then
puriﬁed by preparative HPLC using an acetonitrile/water solvent
system (with or without 0.05% TFA). The collected fractions from
several rounds of HPLC were pooled and the solvent removed under a
vacuum. HPLC-grade solvents were used as purchased. HRESIMS
data for the puriﬁed compounds was obtained from a Waters
Micromass Q-TOF Micro mass spectrometer. All NMR data was
acquired on a Varian INOVA 500, except the 1H, HSQC and
HMBC−15N data for 2 which was acquired on a Varian INOVA 600
ﬁtted with a cryoprobe.
Puriﬁcation of 1. Compound 1 was puriﬁed by HPLC using 80%
acetonitrile/water mobile phase containing 0.05% TFA. Solvent was
removed under a vacuum to aﬀord 1 (1.3 mg); HRESIMS m/z
233.1883 [M + H]+ (Calcd for C16H25O 233.1900; Δ −7.3 ppm); 1D
and 2D NMR data (Supporting Information Table S5; Figure S6).
Puriﬁcation of 2. Compound 2 was puriﬁed by HPLC using 40%
ACN/20% water mobile phase containing 0.15% TFA. Removal of
solvent under a vacuum yielded 2 (0.4 mg); HRESIMS m/z 398.1994
[M + H]+ (Calcd for C20H32NO5S 398.1996; Δ −0.5 ppm); 1D and
2D NMR data (Supporting Information Table S2; Figure S7).
Puriﬁcation of 6. The crude extract from a PDB culture (500 mL)
was subjected to ﬂash chromatography over end-plugged C18. The
fraction containing 6 was dried under a vacuum and the residue further
puriﬁed by HPLC using an 85% ACN/15% water mobile phase.
Solvent was removed under a vacuum to aﬀord 6 (1.1 mg); λmax = 373
nm; HRESIMS m/z 245.1875 [M + H]+ (Calcd for C17H25O
245.1900; Δ −10.2 ppm); 1D and 2D NMR data (Supporting
Information Table S4; Figure S8).
Puriﬁcation of eqxTyr 7. A portion of the semipuriﬁed fraction
from ﬂash chromatography over end-plugged C18 was further puriﬁed
by HPLC using a 75% ACN/25% water mobile phase containing
0.05% TFA. The collected fractions were pooled and solvent was
removed by vacuum to aﬀord an oﬀ-white powder (0.9 mg);
HRESIMS m/z 436.2492 [M + H]+ (Calcd for C27H34NO4
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436.2482; Δ 2.3 ppm); 1D and 2D NMR data (Supporting
Information Table S3; Figure S9).
Puriﬁcation of 8. Compound 8 was puriﬁed by HPLC using a 67%
ACN/33% water mobile phase containing 0.05% TFA. Solvent was
removed to aﬀord 8 (1.8 mg); HRESIMS m/z 291.1963 [M-H]−
(Calcd for C18H27O3 291.1966; Δ 1.0 ppm); 1D and 2D NMR data
(Supporting Information Table S7; Figure S10).
Characterization of 3, 4, and Dihydromonacolin L. These were
characterized by comparing UV absorbance data, m/z values, and MS
fragmentation to previously reported data.10,25
Characterization of 5. Compound 5 was puriﬁed by preparative
HPLC with a gradient running from 30% to 70% acetonitrile/water in
20 min. Pooled fractions from several rounds of HPLC were dried
under a vacuum to aﬀord 5 (1.1 mg); HRESIMS m/z 193.0863 [M +
H]+ (Calcd for C11H13O3 193.0859; Δ 2.1 ppm). 1H NMR spectra
displayed broad signals in both CDCl3 and CD3OD, and 2D NMR
showed weak signals. On the basis of this NMR data, we predicted 5 to
be an unsaturated pyrone.12 After puriﬁcation, 5 was kept in the dark,
under argon. 1H and COSY NMR data indicated an unsaturated side
chain as shown in the structure diagram, but like other compounds in
this class12 the compound was not suﬃciently well behaved for NMR
characterization. Therefore, characterization of 5 was done by
comparative gas chromatography-electron impact-MS (GC-EI-MS)
with a sample of 4. To dried samples, methoxyamine hydrochloride
(40 μL, 40 mg mL−1 in pyridine) was added and the mixture heated at
40 °C for 1 h. After cooling, MSTFA (40 μL) was added and the
reaction mixture was left at rt for 12 h. GC/MS analyses were
conducted using an HP6890 instrument interfaced with an MSD-
HP5973 detector and equipped with a Zebron ZB-5MSi Guardian (30
m × 0.25 mm ID, 0.25 μm ﬁlm thickness; Phenomenex) column and
an HP7682 injector. Helium was used as a carrier gas with a 100:1 split
ratio at an injection volume of 1 μL. The injector temperature was set
to 250 °C. The oven temperature gradient was programmed as
follows: 95 °C held for 1.5 min increased at a rate of 40 °C/min to 118
°C, held for 1 min, increased at a rate of 5 °C/min to 250 °C,
increased at a rate of 25 °C/min to 330 °C and held for 12.3 min. MS
spectra were obtained in EI mode within a range of m/z 50−500.
Other parameters: MS quad and source temperatures were set to 150
and 230 °C, respectively; solvent cut time was 4 min; and scanning
was done at 16 scans/sec. MS fragmentation clearly supported the
proposed structure 5; see Supporting Information Table S8.
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The general strategy was to amplify the genes from genomic DNA or previously subcloned coding 
sequences by PCR, and then insert them into expression vectors by yeast recombination. These vectors 
possessed the C-terminal sequence of either eqxS or fsdS, starting at the ACP and ending with the R 
domain. A C-terminal sgfp tag was utilized to select for protein-expressing clones by visualization on a 
Dark Reader (Clare Chemical).1 The eqxS-fsdS and fsdS-eqxS clones were not tagged with sgfp, while all 
others were initially tagged for analysis. We found no difference in compound production for the reported 
constructs with or without the gfp tag, so that all constructs described in the manuscript result from 
vectors with gfp. The general shuttle vector construction and fungal transformation methods were 
previously described.1  
Construction of Vectors. 
FH-100 (eqxNRPSgfp): The eqxS NRPS (ACP inclusive) was amplified with primer pair 
vector2ACATR-F / eqxSNRPS-sGfp-R from eqxS coding sequence and cloned into vector FH-2.1 
FH-101 (fsdNRPSgfp): The fsdS NRPS (ACP inclusive) was amplified with primer pair d3p-FsdNRPS-F 
/ fsdNRPSgfp-R from previously reported plasmid deg2ACP-CATR2 and cloned into PmeI-linearized 
FH-2. 
FH-102 (eqxNRPS): The vector FH-1 was digested with NotI and PacI, and the fragment spanning the 
eqxS NRPS was cloned into FH-2 by yeast recombination, replacing the sgfp sequence.  
FH-200 (eqxC+eqxNRPS): The fragment from the restriction enzyme digest of FH-11 with NotI and PacI, 
spanning the eqxS ACP-C-A-T-R was cloned into PmeI-linearized FH-2 by yeast recombination to 
replace the sgfp sequence. 
FH-201 (eqxC+fsdNRPS): The fsdS NRPS sequence (ACP inclusive) was amplified from the previously 
reported deg2ACP-CATR plasmid2 with primer pair d3p-fsdNRPS-F / d3p-fsdNRPS-R and subcloned 
into PmeI-linearized FH-1.1 The resultant plasmid was digested with NotI and PacI, and the fsdS NRPS 
containing fragment transformed into yeast together with PmeI-linearized FH-2 for recombination to 
replace the sgfp sequence. 
FH-300 (lovC+eqxNRPSgfp): The eqxS NRPS sequence was as described for vector FH100 and cloned 
into previously reported hphlovC+sGFP plasmid.1 
FH-301 (lovC+fsdNRPSgfp): This vector was made similarly by cloning the fsdS NRPS sequence, 
amplified as described for FH101, into the hphlovC+sGFP plasmid.1 
Construction of fungal expression plasmids.  
The plasmids for expressing the PKS/NRPS gene fusions were constructed by amplifying the PKS 
sequence of the target gene by PCR, and then cloning this amplicon into the respective vector which had 
been linearized with PmeI. The recombination was done by transforming the DNA fragments into S. 
cerevisiae BY4741 to create the desired fusion. Table S2 summarizes the pairings of primers for each 
fusion construct made, the template DNA used for PCR, and the vector into which the amplicon was 
cloned. 
The fusion of full-length lovB with the fsdS NRPS within the adenylation domain was obtained by 
amplifying the lovB sequence from plasmid YEp-ADH2p-lovB-His with primer pair LovPKS-F / 




transformed into Fus?eqx5 with plasmid pyrGlovC+sGfP which was made by replacing the eqxC 
sequence in FH-4 with the lovC sequence. 
KR domain swap: The sequences overlapping the eqxS KR were cloned into plasmid M1192 (Stillman 
Lab, University of Utah) to make plasmid YEpPKSlessKRgfp. The lovB KR sequence was amplified with 
primer pair LovB_KR-F / LovB_KR-R from plasmid YEpADH2p-lovB-His. The SexAI / AflII cut 
amplicon was ligated into YEpPKSlessKRgfp linearized with the same enzymes. The resultant plasmid 
YEpLovBKR was cut with AscI / PacI, and 4.7 kbp fragment co-transformed with the large fragment 
from an AleI digest of hpheqxC+eqxS into yeast for recombination. The resultant plasmid 
hpheqxC+eqxS*lovBkr was used for fungal expression. To make the fsdS NRPS fused construct, the 
primer pair deg3vect_1f / EqxA2C-d2-R was used to amplify the PKS sequence from 
hpheqxC+eqxS*lovBkr which was cloned into PmeI-cut FH-201.   
Recombinant proteins are translated 
Out of the 32 PKS-NRPS gene fusions, 16 led to functional products. A remaining question was whether 
those 16 failed fusions were actually translated. As alluded to in the manuscript, several different gene 
fusions were expressed both with and without covalent C-terminal sGFP tags (22 in total, including all 16 
that did not lead to functional products). When transferred to F. heterosporum, all 22 GFP-tagged mutants 
were fluorescent under conditions that induce the expression system, indicating that the desired gene 
products were translated. In addition, both GFP-tagged and untagged versions led to production of 
identical compounds (or both to no compounds) in F. heterosporum, as gauged by comparing their 
HPLC-DAD and HPLC-MS profiles.  
In addition, all of the proteins used are competent catalysts absent their fusion partners. For example, we 
previously expressed cpaS, which produced 1 g kg-1 of the expected product.1 For the remainder of 
proteins used, all are functional in at least one fusion construct described in this study. All of the genes 
expressed comprise intron-less DNA, with the exception of fsdS, which contains its native introns but 





Table S1. Primers used in this study 








































































































































































































































































































































































































































































































































































































































































































Table S3. NMR data for eqxTyr 7 in methanol-d4. Accompanying figure shows key 2D NMR data. 
                   
Position ?C  ?H (multiplicity, J in Hz) 
1 204.3 C  
2 51.8 C  
3 43.6 CH 3.34 (m) 
4 131.7 CH 5.51 (ddd, 10.0, 4,0, 3.3) 
5 130.2 5.27 (d, 10.0) 
6 35.8 1.92 (brs) 
7 42.0 1.61 (brd, 12.0) 
  1.12 (dd, 12.0, 5.4) 
8 29.6 1.34 (m) 
9 36.7 1.69 (m) 
  0.89 (m) 
10 24.0 1.61 (brd, 12.0) 
  1.46 (dt, 13.0, 12.0) 
11 37.9 2.73 (brs) 
12 23.1 0.87 (d, 5.9) 
13 127.8 5.44 (m) 
14 133.5 5.44 (m) 
15 17.9 1.66 (d, 4.9) 
16 18.9 1.26 (s) 
17  nd 
18 nd  
19 nd nd 
20 nd  
21 49.2 3.98 (brs) 
22 37.3 2.99 (m) 
23 127.5  
24 131.6 6.96 (d, 8.0) 
25 116.0 6.65 (d, 7.9) 
26 157.2  





























Table S4. NMR data for 6 in dmso-d6. Accompanying figure shows key 2D NMR data. 
                   
Position ?C  ?H (multiplicity, J in Hz) 
1 200.5  
2 124.9 6.18 (d, 15.8) 
3 146.7 7.25 (d, 15.8) 
4 133.4  
5 140.5 6.64 (m) 
6 126.1 6.64 (m )  
7 144.0 6.56 (d, 12.5) 
8 133.1  
9 139.2 6.12 (s) 
10 134.1  
11 128.4 5.57 (q, 6.7) 
12 14.6 1.70 (d, 6.7) 
13 33.5 2.59 (q, 7.5) 
14 8.9 0.98 (t, 7.5) 
15 12.8 1.90 (s) 
16 14.4 1.95 (s) 














Table S5. NMR data for 1 in chloroform-d. Accompanying figure shows key 2D NMR data. 
                   
Position ?C  ?H (multiplicity, J in Hz) 
1 198.8  
2 128.8 6.08 (d, 15.9)  
3 143.7 7.08 (dd, 15.9, 10.0) 
4 145.7 6.19 (m) 
5 144.0 6.18 (m) 
6 30.8 2.23 (m) 
  2.18 (m) 
7 35.4 1.49 (m) 
  1.26 (m) 
8 32.9 1.52 (m) 
9 40.1 2.05 (ddd, 13.7, 7.3, 6.1)  
  1.94 (ddd, 13.7, 7.3, 7.2) 
10 129.9 5.52 (dt, 14.6, 7.5) 
11 131.7 5.97 (dd, 13.0, 10.5) 
12 131.6 6.02 (dd, 13.0, 10.3) 
13 127.0 5.61 (dt, 13.6, 6.8) 
14 18.1 1.74 (d, 6.8) 
15 27.2 2.27 (s) 


















Table S6. NMR data for 2 in methanol-d4. Accompanying figure shows key 2D NMR data. 
                   
Position ?C  ?H (multiplicity, J in Hz) 
1 174.0  
2 36.7 3.09 (m) 
3 119.1 5.65 (dt, 15.0, 7.3) 
4 143.8 5.37 (dd, 15.0, 9.7) 
5 48.1 3.26 (m) 
6 31.8 1.60 (m) 
  1.49 (m) 
7 33.6 1.42 (m) 
  1.31 (m) 
8 32.9 1.49 (m) 
9 39.4 2.05 (m) 
  1.90 (ddd, 14.3, 7.2, 6.7) 
10 129.5 5.49 (dt, 14.3, 7.2) 
11 131.7 5.97 (m) 
12 131.6 6.01 (m) 
13 126.1 5.57 (dq, 7.2, 6.7) 
14 16.5 1.71 (d, 6.8) 
15 18.6 0.86 (d, 6.8) 
16 172.3  
17 52.6 4.56 (t, 5.9) 
18 31.7 2.89 (dd, 13.0, 5.7)  
  2.83 (dd, 13.0, 6.6) 
19 171.7  



























Table S7. NMR data for 8 in methanol-d4. Accompanying figure shows key 2D NMR data. 
                   
Position ?C  ?H (multiplicity, J in Hz) 
1 175.6  
2 42.0 2.47 (m)  
3 75.2 4.40 (t, 7.3) 
4 137.4  
5 127.8 5.44 (t, 7.3) 
6 26.2 2.05 (m) 
7 37.4 1.40 (m) 
  1.21 (m) 
8 34.2 1.54 (m) 
9 41.4 2.10 (m) 
  1.96 (ddd, 14.7, 7.9, 7.8) 
10 133.4 5.61 (m) 
11 133.3 6.05 (m) 
12 131.9 6.01 (m) 
13 132.2 6.07 (m) 
14 133.5 6.06 (m) 
15 129.6 5.64 (m) 
16 18.5 1.75 (d, 6.5)  
17 11.8 1.64 (s) 


















Table S8. Comparative GC-EI-MS data for compounds 4 and 5 showing the MS fragments observed.  
                                            
 
Position Compound 4 Compound 5 
Fragment 1 observed mass 
(calcd.) Da 
Fragment 2 observed mass 
(calcd.) Da 
Fragment 1 observed mass 
(calcd.) Da 
Fragment 2 observed 
mass (calcd.) Da 
1 277 (277)  249 (249)  
2 183 (183)  183 (183) 81 (81) 
3 212 (211) 81 (81) 195 (196) 69 (68) 
4 249 (251)  207 (209)  
5   221 (222)  
6   235 (235)  
 
  




Figure S1. Analytical HPLC-DAD of crude extracts of PDB cultures of Fus?eqx5 transformed with psoA-





Figure S2. Analysis of crude extracts of CGA cultures of Fus?eqx5 transformed with lovB-eqxS fusions. 







Figure S3. Analytical HPLC-DAD of crude extracts of PDB cultures of Fus?eqx5 transformed with eqxS-




Figure S4. Analytical HPLC-DAD of crude extracts of PDB cultures of Fus?eqx5 transformed with fsdS-





Figure S5. LC/MS analysis of a crude extract of a PDB culture of Fus?eqx5 co-expressiong eqxC and the 
gene fusion of full-length lovB with the fsdS NRPS within the A domain. Controls were the gfp-
expressing mutant, and the mutant expressing lovC and lovB.1 
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Nontransferability of genetic techniques between fungi is the major hindrance to 
progress in genome-guided natural product discovery in fungi.1,2 This has led to the 
development of heterologous expression systems such as the high-yielding platform 
described in Chapter 3, which has been applied to different biosynthetic questions in 
Chapters 3, 4, and 5. To enable the work thus far described, new transformation procedures 
for Fusarium heterosporum had to be developed. A previously reported protocol for this 
strain was found to be ineffective in my hands.3 Based on ideas and troubleshooting from 
reported studies of other filamentous fungi,2,4–7 a new protocol was crafted. Below is the 
detailed procedure for transformation of Fusarium heterosporum ATCC 74349 (FusWT) 
and the derivative expression strains Fus?eqx5 and Fus?eqx5?pyrG10, the uracil 
auxotroph.  
 
6.2 Transformation Procedure 
Spores are harvested from a 2-week old potato dextrose agar (PDA) culture of 
FusWT or Fus?eqx5 by adding sterile water (8 mL) to the plate and scraping the fungal 
growth surface with an inoculating loop. The spore suspension is then filtered through a 
cotton plug and added to potato dextrose broth (PDB, 100 mL) in a 500 mL Erlenmeyer 
flask. The spores are then germinated by incubation at 30 °C with shaking at 180 rpm for 
8–10 hrs until the 10-cell mycelial stage. It is crucial to monitor growth every 30 mins after 
the 8-hr mark to ensure that the mycelia do not grow beyond this stage; otherwise 
protoplasting becomes inefficient. The germinated spores are then transferred to two 50 
mL conical tubes and pelleted by centrifuging at 3220 x g. The pellets are resuspended in 
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Buffer A and combined. The germinated spores are then washed twice in Buffer A (50 mL) 
and then resuspended in protoplasting solution. Protoplasting is then done by incubating 
this suspension at 30 °C with shaking at 50 rpm for 1.5–3 hrs. It is important to monitor 
this process every 30 minutes after 1.5 hrs of cell wall digestion, and protoplasting is judged 
complete after 80% of the mycelia have been digested. The suspension is then filtered 
through MiraCloth (Calbiochem; sterilized by autoclaving), and the filtrate is centrifuged 
at 2880 x g at 4 °C for 10 mins. The pellet is washed thrice with ice-chilled SC buffer (15 
mL), gently resuspended and centrifuged at 2880 x g for 5 mins. The protoplasts are 
resuspended in ice-chilled SPTC buffer (500 ?L). The protoplast are then diluted with more 
ice-chilled SPTC to obtain 108 protoplasts per mL with the aid of a hemocytometer. Of 
importance, protoplasts should never be mixed by pipetting, but rather by gentle tapping 
on the tube.  
To linearized DNA (10–15 ?g, not exceeding 20 ?L volume) in a 1.7 mL 
microcentrifuge tube is added protoplasts (100 ?L). The mixture is suspended by gently 
tapping on the tube and then kept on ice for 30 mins. 40% PEG solution (1 volume) is 
added and after mixing, the transformation mix is incubated at RT for 50 mins. The 
protoplasts are washed by adding SC buffer (500 ?L) at RT. The tube is inverted 8 times 
to mix and then centrifuged at 2000 x g for 5 mins. This wash step is repeated twice more 
with SC buffer (750 ?L) at RT. The final washed pellet is resuspended in SC buffer (100 
?L) and to this, regeneration broth (400 ?L; 1 M sucrose, 0.02% yeast extract (Difco), 
filter-sterilized) is added and incubated for 17–24 hrs at 30 °C (static culture). Plating is 
done by pipetting the regenerated protoplasts into four petri dishes. Molten regeneration 
agar (1 M sucrose, 0.02% yeast extract (Difco), 1% agar (Difco), autoclaved) at ~42 °C 
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containing selective agents (hygromycin (Invitrogen, Cat no. 10687-010), 150 ?g mL–1; or 
phleomycin (InvivoGen, Cat no. ant-ph-1), 150 ?g mL–1) is poured over the protoplasts, 
which are then embedded in the agar by gentle swirling of the plates.  The agar is allowed 
to set and cool (~10 mins), and then the plates are sealed with Parafilm and incubated at 30 
°C. Transformants that appear after 3–5 days are transferred to PDA containing appropriate 
selection by picking mycelial agar plugs with pipette tips and placing them on the surface 
of the destination plate. After the second round of selection, each transformant is cultured 
to sporulation by streaking PDA with mycelia scraped from the edge of the colony.   
Several modified protocols can also be used for different applications. The most 
useful strain for engineering is Fus?eqx5?pyrG10, in which the equisetin cluster has been 
deleted and uracil is required for growth. This strain lacks any background production of 
secondary metabolites. Additionally, I describe below a protocol to simultaneously 
introduce multiple vectors into Fus?eqx5?pyrG10. This protocol is necessary for pathway 
engineering and has so far been used to express up to four genes simultaneously.   
 The transformation protocol for the Fus?eqx5?pyrG10 strain is similar to that 
described for the FusWT and Fus?eqx5 strains, except that spores are germinated in PDB 
containing uracil (1.12 g L–1) and uridine (140 mg L–1, freshly prepared and filter-sterilized 
and added just before culture).  Also for this strain, regeneration in broth culture before 
plating is not necessary. Immediately after washing the PEG out of the protoplasts, the 
protoplasts are plated by embedding in molten MM regeneration agar (1 M sucrose, 0.02% 
yeast extract without amino acids, 0.02% BSM supplement, 1% agar), and the plates are 
incubated at 30 °C. Transformants are passed through a second round of selection on 
Czapek-Dox agar, and sporulation can then be done by culturing the mutants on PDA.   
167 
 
 Cotransformation of the Fus?eqx5?pyrG10 strain with two vectors containing hph 
and pyrG genes for selection has also been possible with a few modifications of the general 
procedure. 1) More protoplasts are added to the linearized DNA (150 ?L of the 108 
protoplasts/mL suspension is used).  2) After washing the PEG out of the transformation 
mix, the protoplasts are embedded in molten MM regeneration agar (15 mL) and incubated 
at 30 °C for 17 hrs. The agar is then overlayed with MM regeneration agar (15 mL) 
containing hygromycin 200 ?g mL–1, and the incubation continued at 30 °C. Transformants 
that appear in the top layer after 3–5 days are then transferred to Czapek-Dox agar 
containing hygromycin 150 ?g mL–1 for a second round of selection. Sporulation of 
isolated mutants can then be attained by culturing on PDA. 
 Of note, 1) Unused protoplasts can be divided into 100 ?L aliquots and stored at -
80 °C for later use; viability is preserved for up to 2 months. 2) Protoplasting enzymes 
should not be thawed. Activity is reduced by repeated freeze/thaw cycles. 3) Phleomycin 
selection is poor with Fusarium heterosporum, but is greatly improved if the medium pH 
is adjusted to within 6.5–7.5. 4) Sporulation of primary cultures started from glycerol 
stocks can be inefficient. The cause of this is unknown, but we speculate it is due to the 
glycerol. Instead, inoculating PDA with spores from a 4-day old primary culture produces 
enough spores for transformations after 2 weeks of culture.  5) The activity of the 
protoplasting enzymes from the suppliers varies by batch. If protoplasting occurs too 
quickly, i.e., is complete in under 1.5 hrs, protoplast survival is low in the subsequent steps. 
It is advised to reduce the amount of Yatalase to 80 mg and ?-glucuronidase to 2.5 mg. 6) 
During protoplasting, the target of 80% digestion is attained when only a fifth of the initial 
mycelial mass is left when observed by light microscopy. This has been found to be the 
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optimal level of digestion to obtain viable protoplasts. The viability of the protoplasts 
reduces when left in the enzyme solution beyond this point. On the other hand, less 
digestion results in lower protoplast yields after filtration through MiraCloth.  
List of Buffers and their composition: 
Buffer A (autoclaved) 
 1.2 M NaCl 
114 mM Na2HPO4 
19.7 mM citric acid 
SC buffer (autoclaved) 
 1.2 M sorbitol 
 100 mM CaCl2 
40% PEG solution (autoclaved) 
 40% w/v PEG 3350 
 1.2 M sorbitol 
 50 mM CaCl2 
 1% v/v 1 M Tris-Cl pH 8.0 solution 
Protoplasting solution (prepared immediately before use; filter-sterilized) 
 Buffer A (20 mL) 
 Lysing Enzymes from Trichoderma harzianum 1 g (Sigma, Cat no. L1412) 
 Yatalase 100 mg (Takara Clontech, Cat no. T017) 
 ?-glucuronidase 4 mg (Sigma, Cat no. G0751) 
 Hemicellulase 20 mg (Sigma, Cat no. H2125) 
SPTC buffer 
 SC buffer (8 mL) 
 40% PEG solution (2 mL) 
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7.1 Conclusions 
 
Limitations to using the fungal polyketide synthases as medicinal chemists in the 
generation of analogues arise from incomplete understanding of how these enzymes 
function. Great strides have been made over the years to understand the functioning of 
bacterial-type PKSs, enabling their application to synthesize new derivatives.1 The sheer 
complexity of the fungal PKS has made such undertakings quite risky for this class of 
natural products and thus the slow progress observed.2 Rather than a brute force approach 
to combinatorial biosynthesis as has been attempted by others,2 the way to mitigate the 
risks is by taking a synthetic biology perspective,3 where PKS function is deconstructed 
into primary components (critical) and secondary components (noncritical) for the task 
desired. For instance, the work described in Chapter 5 involved the categorization of 
ACP/C domain interactions and C domain selectivity as primary and other domain 
activities as secondary components. This reduced the complexity enough to enable the 
disentanglement of C domain selectivity from PKS/NRPS interactions in the study 
design. While the results from this work show that analogue synthesis by combinatorial 
PKS/NRPS pairings is more difficult than anticipated, it establishes ground rules for 
these attempts and opens up new avenues for inquiry. For example, the characterization 
of more PKS-NRPSs and linking them to products becomes more appealing. With more 
members identified, a phylogenetic-guided approach to combinatorial biosynthesis 
becomes possible. Another possibility is leaving the ACP and C domain intact and 
modifying the components upstream or downstream. For example, upstream of the ACP, 
the KR domain was manipulated, but it did not produce the desired outcome. A shift of 
focus downstream to the A domain, altering its amino acid specificity via a directed 
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evolution approach, could allow the installation of various amino acids to a fixed 
polyketide chain to generate tetramic acid analogues. The identified specificity 
determinants within A domains could then be engineered into already characterized PKS-
NRPSs to modify their native products. Beyond combinatorial biosynthesis, the results 
from the PKS-NRPS study could be applied from a biotechnology perspective to supply 
crucial intermediates for chemical synthesis. The observation that complete PKS modules 
fused to highly-selective C domains leads to synthesis of predicted polyketide products 
native to that PKS allows the decoupling of these polyketides from amino acids in a 
predictable manner such that the isolated intermediates can be repurposed. Using the 
model expression platform described in Chapter 3, these intermediates could be supplied 
in yields high enough for use as starting materials for chemical synthesis protocols. In 
line with this reasoning, this expression platform allows a semisynthetic approach to 
doing medicinal chemistry on promising compounds for drug development. For example, 
the pyrrolocins described in Chapters 3 and 4 were produced in excess of 800 mg kg–1 
such that chemical modifications can now be pursued to determine structure activity 
relationships starting from the core structure isolated from the recombinant strain.   
In this work, all the research questions posed were answered. More exciting, 
however, was that more questions arose from observations made on this long arduous 
journey. One example is the mysterious heterologous production of a mixture of 
pyrrolocin stereoisomers about the decalin ring, whereas only the trans-isomer was 
produced by the native host. This result raised the possibility of the involvement of a 
third protein that catalyzes the Diels-Alder reaction, and further suggests that other PKS-
NRPS pathways to decalin-containing tetramic acids possess this component.  Another is 
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the observation that Dieckmann reaction capabilities of the R domain are compromised 
with the attachment of a gfp tag. One hypothesis is that normally, water is excluded from 
the R domain active site but the tag modifies the structure sufficiently to promote a 
water-mediated hydrolysis catalyzed by the R domain. Further investigations into this 
phenomenon guided by R domain structural data will illuminate the sequence features 
that led to the divergence of these types of R domains from those that actually perform 
NAD(P)H-reductive release of their substrates. A third unexpected finding was the 
methylation of pyrrolocin by an equisetin pathway N-methyl transferase (MT). The 
structure of the native substrate for this MT is quite different from the pyrrolocin 
structure allowing the possibility that this MT could be repurposed for N-methylation of 
other small molecules. Structural studies will be required to delineate the active site such 
that a broad substrate mutant can be designed. Finally, the most intriguing question is 
why C domains select for a set of closely related substrates. A definitive answer will be 
difficult to come to, absent a crystal structure of the C domain. Currently, common length 
of substrates within error of one ketide unit appears to be the most consistent feature that 
can be attributed to C domain selectivity. This suggests that the size of substrate-binding 
pocket of the C domain is finely tuned to position the substrate for conjugation to the 
amino acid. Also the size of the substrate could be critical to exclude water from the 
active site, akin to the observation for the gfp-tagged R domain.  However, based upon 
the observation that competition for substrates between the KR and C domain exists, it is 
possible that KR and C domains coevolved to maintain a balanced affinity for 
intermediates during polyketide elongation. This idea is supported by phylogenetic 
analyses of PKSs and NRPSs from these hybrid enzymes that show that the family trees 
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obtained are similar.2 Beyond further work in combinatorializing PKS-NRPSs, future 
studies directed towards all the above mentioned observations will push the field forward.  
In closing, fungi still remain a promising source of natural products that will 
impact human health, and elucidation of biosynthetic mechanisms should continue to be a 
priority to augment the structural diversity found in nature. 
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